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ABSTRACT 
DEFINING A T CELL-INTRINSIC ROLE FOR MYD88 DURING LCMV 
INFECTION 
Adeeb Habibur Rahman 
Laurence Turka, M.D. 
 
Immune activation through Toll-like receptors (TLRs) has historically been considered to 
be a characteristic of cells of the innate, rather than adaptive immune system. Recent 
studies have challenged this paradigm by demonstrating that TLRs are also expressed on 
T lymphocytes and that TLR ligands can directly co-stimulate T cell responses in vitro. 
However, the physiological relevance of these findings during in vivo immune responses 
was unclear. Mice lacking the critical TLR-adapter protein, myeloid differentiation 
protein 88 (MyD88), have increased susceptibility to numerous pathogens, highlighting 
the importance of TLRs in host defense. While the immune impairments associated with 
MyD88-deficiency have generally been attributed to the importance of MyD88 in 
regulating innate immune responses, in light of the studies showing that TLRs can 
directly stimulate T cells, we hypothesized that they may also reflect a direct role for 
MyD88 in T cells. In this work, we use lymphocytic choriomeningitis virus (LCMV) as a 
model infection to examine the role of MyD88 in regulating antiviral T cell responses. 
Using a series of adoptive cell transfer and bone marrow chimera experiments, we 
identify a critical, but previously unappreciated, T-cell intrinsic role for MyD88 in 
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regulating the survival and expansion of LCMV-specific effector T cells during acute 
viral infection. Using a system to inducibly delete MyD88 we also show that, while naïve 
T cells critically depend on MyD88-dependent signals for their expansion, virus-specific 
memory T cells do not require MyD88 for their differentiation, maintenance or 
reactivation in response to secondary infection. Overall, our findings broaden the 
importance of MyD88 in T cells, support a shift in the dogma that restricts the role 
MyD88 to cells of the innate immune system, and may have significant implications for 
understanding the signals that control T cell survival during inflammatory immune 
responses. 
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CHAPTER I: Introduction and Overview 
 
Introduction 
The immune system can broadly be divided into two arms: the innate and adaptive. The 
innate immune system serves as a first line of defense against pathogens and also plays 
an important role in initiating and directing adaptive immune responses. Cells of the 
innate immune system, such as neutrophils, macrophages and dendritic cells, recognize 
foreign antigens through a limited range of germ-line encoded receptors, collectively 
known as pattern recognition receptors (PRRs)(Janeway & Medzhitov 2002). These PRRs 
recognize highly conserved molecular motifs that are generally found in microbial 
pathogens, but not in their eukaryotic hosts and are thus termed pathogen-associated 
molecular patterns (PAMPs). In contrast, cells of the adaptive immune system, such as B 
and T lymphocytes are activated through antigen receptors that are generated by genetic 
rearrangement and selected to recognize an incredibly diverse array of potential 
ligands(Oettinger et al. 1990). Thus, activation through PRRs, versus rearranged antigen 
receptors, has historically been considered a defining feature that distinguishes cells of 
the innate arm from those of the adaptive arm of the immune system. 
 
Toll like receptors 
Several classes of PRRs have been now described, but Toll like receptors (TLRs) 
represent one of the best characterized. TLRs are a family of evolutionarily conserved 
receptors that have a broad, heterogeneous tissue expression pattern, and whose ligands 
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can mediate effects on a variety of cell types. The TLR family currently includes at least 
11 members that bind to a range of microbial components from bacteria, fungi and 
viruses. TLRs 2, 4, 5 and 11 are expressed on the cell surface and recognize bacterial 
lipoproteins, lipopolysaccharide (LPS), flagellin and profilin respectively. TLRs 3, 7, 8 
and 9 are expressed in endosomal compartments and are involved in the recognition of 
double stranded RNA, single stranded RNA, and unmethylated CpG DNA, respectively. 
These details of TLR ligand-recognition and cellular localization are summarized in 
Table 1. The molecular mechanisms that allow for the broad diversity in TLR ligand 
recognition remain unclear and recent studies of the structure of TLR receptor-ligand 
complexes suggest that different TLRs may employ different ligand-binding interfaces(Jin 
et al. 2007)(H. M. Kim et al. 2007)(L. Liu et al. 2008).  
While TLRs have generally been considered a means to distinguish “non-self” 
from “self”, it is interesting to note that endogenous molecules may also act as TLR 
ligands. In analogy to PAMPs, these putative endogenous ligands may be considered 
damage associated molecular patterns (DAMPs)(Bianchi 2007). Heat shock proteins 
(HSPs), and extracellular matrix components such as fibronectin and hyaluronan are 
released during stressful tissue injury and have been reported to activate the innate 
immune system through TLR2 and TLR4(Vabulas et al. 2001)(Ohashi et al. 2000)(Okamura 
et al. 2001)(Termeer et al. 2002), though the potential contamination of these endogenous 
ligands with PAMPs is a concern in some of these studies(Gao & Tsan 2003a)(Gao & Tsan 
2003b). In addition, chromatin complexes released from damaged cells contain nucleic 
acids that can engage TLR7 and TLR9(Leadbetter et al. 2002)(Lau et al. 2005). Indeed, it 
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has been suggested that the intracellular localization of these nucleic acid-sensing TLRs 
restricts their access of to endogenous ligands and thereby contributes to the 
discrimination between self and non-self nucleic acids(Barton et al. 2006). However, this 
discrimination is imperfect and, consequently, TLR-mediated recognition of endogenous 
nucleoproteins has been implicated in the development and progression of autoimmune 
diseases such systemic lupus erythamtosis (SLE)(Christensen et al. 2006)(Ehlers et al. 2006). 
These studies highlight the fact that the TLR family plays a role in the recognition of an 
incredibly broad array of ligands, the overall diversity of which may yet to be fully 
appreciated. 
 
TLR signaling 
TLRs are type I integral membrane glycoproteins that contain a leucine rich repeat motif, 
which serves as a ligand binding domain, and an intracellular cytoplasmic 
Toll/interleukin-1 receptor (TIR) domain that initiates signal transduction(Jin et al. 
2007)(Jin & Lee 2008). The super-family of TIR-domain containing receptors also includes 
the IL-1R/IL-18R family(Adachi et al. 1998). These receptors act by recruiting and 
homodimerizing with TIR domain-containing adaptors proteins. Myeloid differentiation 
protein 88 (MyD88) is one of several adapter proteins linking these receptors to 
downstream signaling molecules(Medzhitov et al. 1998). Importantly, MyD88 is required 
for signaling through all TLRs except TLR3, which signals through the alternate adaptor 
molecule, Toll/IL-1R domain containing adaptor-inducing IFN- (TRIF), and TLR4, 
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which can signal through both MyD88- and TRIF-dependent pathways(Yamamoto et al. 
2002)(Yamamoto et al. 2003).  
Following interaction with upstream receptors through its TIR domain, MyD88 
recruits downstream signaling molecules through its death domain. Homotypic death-
domain interactions lead to the activation of IL-1 receptor-associated kinases (IRAKs) 
and the subsequent activation of TNF receptor-associated factor 6 (TRAF6), ultimately 
resulting in the activation of NFB and AP-1(Wesche et al. 1997)(Martin & Wesche 2002). 
While the nuclear translocation of NFB is generally considered to be classical outcome 
of MyD88-dependent signaling pathways, numerous studies have established that there is 
considerably more diversity and complexity in the potential signaling pathways that can 
be induced through MyD88. For example, TLR signaling can also activate the Akt 
pathway through a direct interaction of phosphatidylinositol 3-kinase (PI-3-K) with a 
tyrosine motif in the MyD88 TIR domain(Li et al. 2003)(Rhee et al. 2006)(Gelman et al. 
2006). MyD88 has also been shown to form complexes with interferon regulatory factors 
(IRF)-1, IRF-5, and IRF-7, which play an important role in the induction of type I 
interferons (IFN-I) and other proinflammatory cytokines by TLR signaling in APCs 
(Balkhi et al. 2008a)(Takaoka et al. 2005)(Kawai et al. 2004)(Honda et al. 2005)(Balkhi et al. 
2008b)(Honda et al. 2004).  
MyD88 has also been found to contribute to pathways outside of its traditional 
role in TLR signaling. The ability of MyD88 to undergo homotypic interactions with 
other death-domain containing proteins has been shown to allow it to interact with Fas-
associated protein with death domain (FADD), implicating MyD88 as a bridge between 
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TLR and Fas-mediated signaling pathways(Altemeier et al. 2007)(Zhande et al. 2007). 
Additionally, MyD88 has been shown to be able to interact with the interferon gamma 
receptor (IFNR1) and stabilize IFN-induced mRNA transcripts(D. Sun & Ding 2006). 
Overall, these studies identify MyD88 as a critical regulator of TLR signaling and an 
important branching point in the diversity of signals and cellular outcomes that can be 
induced through TLR stimulation and other potential upstream mediators.  
 
TLRs stimulate antigen presenting cell responses 
TLRs are highly expressed on antigen presenting cells (APCs) of the innate immune 
system, such as macrophages and dendritic cells, and have been most extensively studied 
in these cell types. TLR engagement induces APC maturation, characterized by increased 
expression of costimulatory molecules such as CD80 and CD86 as well as the production 
of pro-inflammatory cytokines such as IL-12, IL-6 and type I IFNs(Fearon & Locksley 
1996)(Krug et al. 2001). Furthermore, maturation precipitates a shift in adhesion molecule 
and chemokine expression allowing APCs to traffic to the T cell areas of the spleen and 
lymph nodes(Michelsen et al. 2001)(Turnbull et al. 2005). TLR engagement also promotes 
the stability of cognate MHC peptide complexes and upregulates their expression on the 
surface of APCs(Hertz et al. 2001)(Rudd et al. 2008), and the presence of TLR ligands in 
phagocytosed antigens has also been shown to promote the generation of peptide:MHC 
Class II complexes thereby directly enhancing the presentation of phagocytosed 
antigens(Blander & Medzhitov 2006). On account of these effects, TLR stimulation on 
APCs allows them to more effectively activate T cells, promoting the proliferation and 
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differentiation of naïve T cells into effector cells. In the absence of these maturation 
signals, the ability of APCs to initiate T cell responses is greatly reduced(Pasare & 
Medzhitov 2004). 
 
TLRs are expressed on B and T lymphocytes 
Due to their importance in the antigen presenting cells, it is well established that TLRs 
also play a key, indirect role in promoting adaptive immune responses. However, recent 
studies have demonstrated that the expression and function of TLRs is not limited to cells 
of the innate immune system. Mouse and human B lymphocytes have been found to 
express several TLRs and TLR stimulation promotes B cell proliferation, differentiation, 
antibody class switching, cytokine production and survival(Pasare & Medzhitov 
2005)(Ruprecht & Lanzavecchia 2006)(Yi et al. 1998). The ability of TLR ligands to modulate 
B cell responses demonstrates that TLRs can directly contribute to adaptive immune 
responses. A number of studies have now further extended these findings to show that 
TLRs are also expressed by various subsets of T lymphocytes. 
In two studies, sorted CD4+CD45RB
high
 T cells from C57BL/6 (B6) mice were 
found to express TLR1, 2, 3, 6, 7 and 8, but low to undetectable levels of TLR 4, 5 and 9 
mRNA(Caramalho et al. 2003)(Tomita et al. 2008). Naïve CD4 T cells from BALB/c mice 
have been shown to express mRNA for TLR3, 4, 5 and 9(Gelman et al. 2004), while naïve 
CD8 T cells from B6 mice have been reported to express mRNA for TLR1, 2, 6 and 9 but 
not TLR4(Sobek et al. 2004)(Cottalorda et al. 2006). Regarding protein expression, TLR2, 3, 
4 and 9 protein have been reported to be found on murine CD4 T cells via flow 
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cytometry(Fukata et al. 2008), and TLR2 protein has been detected by flow cytometry on 
murine CD8 T cells(Sobek et al. 2004)(Cottalorda et al. 2006). Furthermore, human T cells 
isolated from peripheral blood have also been reported to express mRNA for most TLRs, 
though there is considerable variation in the reported expression levels in these 
studies(Hornung et al. 2002)(Mansson et al. 2006)(Zarember & Godowski 2002). Protein 
expression of TLR2, 3, 4, 5, 9 has also been detected by flow cytometry on human T 
cells(Mansson et al. 2006)(Crellin et al. 2005)(Komai-Koma et al. 2004)(Wesch et al. 2006). 
Stimulation through the B cell receptor has been shown to upregulate TLR 
expression on B cells, resulting in enhanced sensitivity to TLR ligands(Ruprecht & 
Lanzavecchia 2006). Similarly, TLR expression on T cells appears to be regulated by T cell 
receptor-dependent activation. Naïve BALB/c CD4 T cells upregulate TLR3 and TLR9 
mRNA in response to T cell receptor (TCR) stimulation by CD3 antibodies(Gelman et al. 
2004). Furthermore, while naïve BALB/c T cells were shown to express intracellular 
TLR2, expression on the cell surface was only readily detectable by flow cytometry 
following CD3-induced activation(Liu et al. 2006). Similarly, B6 CTLs express higher 
levels of TLR2 mRNA than naïve CD8 T cells(Sobek et al. 2004) and TCR stimulation 
increases surface expression of TLR2 protein as detected by flow cytometry(Cottalorda et 
al. 2006). Antigen experienced T cells appear to continue to maintain higher levels of TLR 
expression since CD4+CD45RB
low
 memory cells have also been shown to express higher 
mRNA levels of most TLRs than naïve CD4+CD45RB
high
 T cells(Caramalho et al. 2003) 
and human CD45RO+ memory CD4 T cells express higher levels of TLR2 than naïve T 
cells(Komai-Koma et al. 2004). 
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To summarize the above, while TLR expression on various T cell subsets has 
been independently confirmed by a number of studies, the specific patterns of expression 
that have been reported vary considerably. Thus there may be significant species, and 
even strain, specific differences in TLR expression. It is also possible that these 
differences in expression result from technical variations in different studies. It is also 
important to note that mRNA levels do not always correlate with protein expression, and 
TLR expression is known to be regulated at the protein level by ubiquitin-mediated 
degradation(Chuang & Ulevitch 2004)(Boone et al. 2004). Furthermore, minimal 
contamination of purified T cells by APCs could significantly influence results. In 
addition, studies that have examined TLR protein levels in T cells are limited by the 
reliability of available antibody reagents and personal experience with reagents to detect 
murine TLRs via flow cytometry has been quite variable. These caveats may partially 
explain the considerable variability in the TLR expression patterns that have been 
reported on T cells. Given the limitations in examining expression levels of TLRs on T 
cells, the ability of known TLR ligands to activate signaling pathways may be a more 
reliable indicator of expression. 
 
TLRs can act as T cell costimulatory receptors 
Effective T cell activation requires a primary signal delivered through the TCR, however 
this signal alone is insufficient to induce effective T cell activation. Optimal expression 
of effector cytokines and the synthesis of pro-survival molecules depend on additional 
secondary signals delivered through co-stimulatory receptors. CD28 is generally 
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considered to be the principle co-stimulatory receptor involved in initial T cell 
activation(Sharpe & Freeman 2002) and early studies using CD28 deficient T cells found 
greatly reduced T cell responses in the absence of CD28 signaling(Lucas et al. 1995). A 
number of studies have now found that TLR ligands can act directly on highly purified 
 T cells to provide costimulatory signals in the absence of traditional CD28 signaling 
from APCs. 
Conventional CD4 and CD8 T cells 
As discussed earlier, mouse and human CD4 and CD8 T cells have been shown to 
upregulate TLR2 expression as a result of activation through the TCR(Komai-Koma et al. 
2004)(Cottalorda et al. 2006). Consistent with the this increased expression, it has been 
demonstrated that the synthetic TLR2 ligand, Pam3CysSK4, can act directly on highly 
purified B6 CD8 T cells to promote enhanced proliferation and survival associated with 
sustained CD25 expression(Cottalorda et al. 2006). TLR2 ligands also promote CD8 T cell 
effector functions such as IFN production, granzyme B secretion and cytolytic activity. 
Costimulation through TLR2 also allows lowers the threshold of activation, thereby 
allowing CD8 T cells to differentiate into functional memory cells in response suboptimal 
levels of TCR stimulation(Mercier et al. 2009). TLR2 has similarly been shown to 
costimulate proliferation and IFN production from B6 mouse CD4 T cells(Rahman et al. 
2009). While purified CD4 T cells from Balb/c mice were reported to not respond to 
TLR2, 5 or 7 ligands, Poly(I:C) and CpG-containing oligonucleotides (CpG-ODN), the 
synthetic ligands for TLR3 and TLR9 respectively, promoted enhanced activated T cell 
survival(Gelman et al. 2004). CpG-ODN have also been shown to support enhanced 
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proliferation and IL-2 production from activated B6 CD4 T cells(Gelman et al. 
2006)(Bendigs et al. 1999) and have recently also been shown to enhance proliferation of 
rat CD4 T cells(Chiffoleau et al. 2007). 
Similarly to mouse T cells, both naïve CD45RA+ and memory CD45RO+ human 
CD4 T cells have been shown to directly respond to TLR2 ligands(Komai-Koma et al. 
2004). However, in contrast to mouse T cells, synthetic ligands for TLR5 and 7/8 have 
also been shown to enhance proliferation and cytokine production in human CD4 T cells, 
particularly in CD45RO+ memory cells(Caron et al. 2005). A recent study has also found 
that human, but not mouse, CD8 T cells produce IFN, perforin and granzyme in 
response to LPS signaling through TLR4(Komai-Koma et al. 2009). In contrast, another 
recent study attributes to the costimulatory effect of LPS on human CD4 T cells to APC 
contamination, but supports a role for direct TLR2 and TLR5 induced signals in 
promoting cytokine production and reducing the threshold for CD4 T cell 
activation(Lancioni et al. 2009). Notably, this study highlights the importance of stringent T 
cell purification methods when studying the direct effects of TLR ligands on T cells since 
minimal APC contamination is sufficient to significantly alter the results of experiments. 
  Overall, these studies demonstrate that several TLR ligands can act directly on T 
cells in vitro, though there are clearly species, and even strain specific differences in the 
ligands that are recognized. It is important to note that these studies consistently show 
that TLR-induced signals in naïve T cells are strictly co-stimulatory, in that TLR ligands 
appear to modulate T cell responses induced by TCR signaling but do not appear to 
produce functional responses in naïve T cells in the absence of concurrent TCR 
11 
 
stimulation. This may reflect the importance of preventing TLR signals from inducing 
non-specific T cell activation. In contrast, after having been activated through their TCR, 
effector and memory T cells appear to maintain responsiveness to TLR ligands in the 
absence of concurrent TCR-induced signals(Gelman et al. 2004)(Cottalorda et al. 2009). 
Functional responses of TLR9-induced co-stimulation in B6 CD4 T cells can be 
attributed to two main signaling pathways mediated by the adaptor molecule, MyD88. As 
has been shown in multiple other cell types, stimulation with CpG oligonucleotides 
(CPG-ODN) induces MyD88-dependent NF-B activation in CD4 T cells through 
homotypic death domain interactions with IRAKs. This NF-B-dependent pathway 
upregulates expression of the anti-apoptotic molecule Bcl-xL, and thereby promotes 
activated CD4 cell survival(Gelman et al. 2004). TLR2 stimulation has been found to 
similarly enhance survival and Bcl-xL expression in activated CD8 T cells(Cottalorda et 
al. 2006). While NF-B activation alone appears to be required for CpG-ODN to induce 
anti-apoptotic signals in T cells, this pathway synergizes with a PI-3-kinase dependent 
pathway in promoting proliferative responses and IL-2 production(Gelman et al. 2006). In 
contrast to the death domain interactions by which MyD88 activates NF-B, MyD88-
dependent PI-3 kinase activation involves a tyrosine residue located in the TIR domain. 
This allows MyD88 to associate with the p85 regulatory subunit of PI-3 kinase and 
induce Akt phosphorylation in response to TLR stimulation(Gelman et al. 2006). Thus, 
specific outcomes of TLR-mediated stimulation in T cells may be associated with 
discrete MyD88 motifs and signaling pathways. It will be of interest to determine 
whether induction of this PI-3-kinase signaling pathway is specific to TLR9, which is 
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expressed intracellularly, or are also shared by other TLRs expressed on the cell surface, 
such as TLR2. 
Interestingly, stimulation of CD4 T cells with TLR ligands also results in 
enhanced expression of secondary co-stimulatory receptors that are generally upregulated 
following initial T cell activation(Rahman et al. 2009). Certain co-stimulatory receptors, 
such as CD154, play an important role in allowing CD4 T cells to promote B cell 
immune responses, which may relate to the finding that MyD88 expression in CD4 T 
cells is critical in supporting B cell-class switching to IgG production in an in vivo model 
of CpG DNA- induced antibody responses against a T cell dependent antigen(Gelman et 
al. 2006). Secondary co-stimulatory receptors can also play an important role in 
supporting sustained T cell responses. For example, signals delivered through OX-40 
serve to enhance CD4 T cell effector responses, survival and IL-2 production(Gramaglia et 
al. 2000). Given that T cell responses induced by these co-stimulatory receptors are quite 
similar to those that occur following TLR stimulation it is possible that, in addition to the 
direct TLR-induced signaling pathways discussed above, some of the functional 
outcomes of TLR stimulation on T cells may reflect secondary consequences of enhanced 
signaling through these induced co-stimulatory pathways. 
 The studies described thus far have focused on survival, proliferation and effector 
cytokine production as readouts of functional TLR responses in T cells. However, in 
considering other aspects of T cell physiology it has been found that LPS treatment 
increased adhesion of mouse and human T cells to fibronectin and inhibited 
chemotaxis(Zanin-Zhorov et al. 2007). Human T cells were also reported to respond 
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similarly to the endogenous ligand HSP60 through TLR2, though these results could 
reflect potential contamination of commercially available HSP60 with bacterial TLR2 
ligands(Zanin-Zhorov et al. 2006). These results suggest that, in addition to enhancing T cell 
effector functions, TLR signaling in T cells may also play a role in controlling T cell 
trafficking. The finding that T cells may potentially respond to endogenous TLR ligands 
is particularly intriguing since this presents the possibility that DAMPs may act to recruit 
T cells and support their responses at sites of tissue inflammation and necrosis. These 
findings also suggest that T cells may respond to a broader range of TLR ligands than has 
been thus far been considered, since functional outcomes may differ in responses to 
specific TLR ligands. 
CD4+CD25+ Regulatory T cells 
The studies discussed thus far indicate that TLR ligands can promote more effective T-
cell mediated immunity by acting directly on conventional CD4 and CD8 T cells to 
enhance their respective effector functions. However, TLR ligands can also influence 
CD4+CD25+ regulatory T cells (Treg). Treg are known to inhibit T cell effector responses 
in vitro, and are critical in maintaining immune tolerance and preventing the development 
of autoimmunity in vivo(Piccirillo & Shevach 2004). As in the case of effector T cells, TLR 
ligands indirectly modulate regulatory T cell responses by promoting inflammatory 
cytokine production in APCs, which can inhibit the suppressive capacity of Treg(Pasare & 
Ruslan Medzhitov 2003). However, it is now clear that TLR ligands can also act directly on 
Treg, though there are differences in the reported outcomes of these actions. 
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The TLR2 ligand, Pam3CysSK4, can act directly on mouse Treg through TLR2 to 
promote their expansion both in vitro and in vivo, which may relate to the reduced 
numbers of Treg found in Myd88-/- and Tlr2-/- mice(Sutmuller et al. 2006). Yet while 
promoting increased proliferation of Treg, Pam3CysSK4 also abrogates their suppressive 
activity, which correlates with a transient suppression of Foxp3 expression(Liu et al. 2006). 
It has also been found that direct TLR8 triggering of human Treg similarly prevents their 
suppressive activity(Peng et al. 2005). It should be noted though that, in contrast to these 
studies, others have found that signals through TLR2 and TLR5 can enhance the 
suppressive function of Treg as well as Foxp3 expression(Crellin et al. 2005)(Zanin-Zhorov et 
al. 2006).  
While TLR ligands may influence suppression in co-culture experiments, this 
potentially reflects the combined result of distinct effects on both conventional T cells 
and regulatory T cells. Indeed, co-culture suppression assays in which MyD88-deficiency 
was restricted to either the responder or Treg population showed that CpG DNA can act 
directly on Treg to block their suppressive activity, but also acts on effector T cells to 
render then resistant to suppression(LaRosa et al. 2007). Interestingly, once TLR ligands 
are removed, Treg fully regain their suppressive phenotypes(Liu et al. 2006)(Sutmuller et al. 
2006).  
Summary 
Overall, these findings suggest a model whereby TLR ligands can act on both effector 
and regulatory T cells to directly promote T-cell mediated immune responses by 
enhancing T cell effector functions and clonal expansion through increased proliferation, 
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survival and a transient loss of suppression. These TLR ligands also serve to concurrently 
expand the Treg population, which regains its suppressive capacity following clearance of 
the TLR ligands and can then act to regulate the expanded effector T cell population at 
the end of the immune response.  
It is important, however, to consider a number of caveats when interpreting the 
results of these in vitro studies. In order to show that TLR ligands are able to act directly 
on T cells, these studies depended on using highly purified T cells. The importance of 
eliminating APCs in these experiments highlights a significant issue: while TLR ligands 
can act directly on T cells, their indirect effects through APCs generally overshadow their 
direct effects on T cell activation in in vitro cultures. In addition, these studies generally 
employ high concentrations of TLR ligands that greatly exceed physiological levels. 
Furthermore, given that TLR signals appear to stimulate different responses in different 
cell subsets, the overall consequence of TLR ligands on T cells in a mixed culture of cells 
is less clear. Overall, these in vitro studies importantly showed that TLR signals have the 
ability to directly stimulate T cell responses. However, the relevance of these signals 
during a physiological immune response in vivo remained unclear. In particular, it was 
not known whether direct TLR signaling contributes to initial T cell activation, effector 
cell differentiation, proliferation, survival or the differentiation and maintenance of 
memory cells during an immune response. These unresolved questions formed the basis 
of my dissertation work. 
 
MyD88 regulates systemic immune responses against pathogens 
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Studies in mice lacking TLRs, or adapter proteins, such as MyD88, have shown that these 
receptors play an important role in regulating systemic immune responses. MyD88-
deficient mice have greatly increased susceptibility to a number of eukaryotic, 
prokaryotic and viral pathogens. These include Toxoplasma gondii(Scanga et al. 2002), 
Mycobacterium tuberculosis,(Scanga et al. 2004) herpes simplex virus(Tengvall & Harandi 
2008), murine cytomegalovirus(Delale et al. 2005), vesicular stomatitis virus (VSV)(Lang et 
al. 2007), vaccinia virus(Zhu et al. 2007) and lymphocytic choriomeningitis virus 
(LCMV)(Zhou et al. 2005). 
In these infection models, the immune impairments associated with MyD88-
deficiency have generally been attributed to the importance of MyD88 in regulating 
innate immune responses. However, in light of the recent studies demonstrating that 
TLRs can directly modulate T cell responses, we thought it important to consider whether 
defective adaptive immune responses in MyD88-deficient mice also reflects a T-cell 
intrinsic role for MyD88. In this work, we use lymphocytic choriomeningitis virus 
(LCMV) as a model infection in which to examine the relative contribution of MyD88 in 
T cells to the overall antiviral T cell response. Using a series of adoptive transfer 
experiments, we show that while MyD88 plays a significant T cell extrinsic role in 
promoting T cell responses, it also play an important T cell intrinsic role in regulating T 
cell expansion during the primary response to acute LCMV infection (Chapter 1). We 
also use an inducible flox-cre system to inducibly delete MyD88 expression after the 
initial phase of T cell expansion to show that MyD88 is not required for the 
differentiation, maintenance and reactivation of memory T cells (Chapter 2). 
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Table 1. TLRs, their ligands and localization 
 
TLR Classical ligands Distribution and cellular localization  
 
TLR1 
 
Mycobacteria: tri-acyl peptides 
 
 
Ubiquitous surface expression in both humans and 
mice. Heterodimerizes with TLR2 
 
 
TLR2 Gram positive bacteria:  peptidoglycan, 
lipoproteins 
Broad surface expression in both humans and 
mice. Also found in phagolysosomes. 
Heterodimerizes with TLR1 and TLR6 
 
 
TLR3 Viruses: double-stranded RNA 
Synthetic: polyinosic polycytidylic acid 
[Poly(I:C)] 
 
Intracellular expression primarily on mDCs in 
humans and monocytes and mesangial cells in 
mice 
 
 
TLR4 Gram negative bacteria: LPS 
(involves coreceptors CD14, LBP and  
MD-2) 
 
Broad surface expression in both humans and 
mice. Intracellular expression in gut epithelium. 
 
 
TLR5 Bacteria:  flagellin Broad surface expression in both humans and mice 
including gut epithelium.  
 
 
TLR6 Mycoplasma: Diacyl lipoproteins 
 
 
Primarily expressed on the surface of mDCs, mast 
cells and B cells. Found in both mice and humans. 
Heterodimerizes with TLR2 
 
 
TLR7 Viruses: single-stranded RNA 
Synthetic ligand: imidazoquinolines 
Endosomal expression primarily by pDCs and B 
cells in humans. Also expressed by mDCs in mice 
 
 
TLR8 Viruses: single-stranded RNA 
Synthetic ligand: imidazoquinolines 
Endosomal expression by human myeloid cells, NK 
cells and T cells. Not reported functional in mice 
 
 
TLR9 Viruses and bacteria: double-stranded DNA 
Synthetic: CpG olidodeoxynucleotides 
Endosomal expression primarily on pDCs, B cells 
and NK cells in humans. Broader tissue expression 
in mice 
 
 
TLR10 Unknown Expressed primarily on the surface of pDCs and B 
cells in humans. Not found in mice 
 
 
TLR11 Toxoplasma gondii: profilin 
Uropathogenic bacteria 
 
Expressed on the surface of murine uroepithelium. 
Not described in humans 
 
 
References: (Hornung et al. 2002)(Ozinsky et al. 2000)(Takeda et al. 2003)(Iwaki et al. 2002)(Aliprantis et al. 1999) 
(Patole et al. 2005)(Alexopoulou et al. 2001)(Muzio et al. 2000) (Jiang et al. 2000)(Akashi et al. 2000) (Hayashi et al. 
2001)(Gewirtz et al. 2001) (Heil et al. 2004)(Jurk et al. 2002) (Hemmi et al. 2000) (Latz et al. 2004) (Yarovinsky et al. 
2005)(Zhang et al. 2004) 
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CHAPTER 2: Materials and Methods 
 
Mice 
C57BL/6 (B6), B6.PL-Thy1
a
/CyJ (B6 Thy1.1), B6.SJL-Ptprc
a
 Pepc
b
/BoyJ (B6 CD45.1),  
B6.129-Tr2
tm1Kir
/J, ( Tlr2-/-), B6.B10ScN-Tlr4
lps-del
/JthJ, (Tlr4-/-), B6.129S7-Il1r1
tm1Imx
/J, 
(IL1r-/-) and B6.129P2-Il18r1
tm1Aki
/J, (IL18r-/-) were purchased from The Jackson 
Laboratory.  Tlr9-/- mice were provided by Robert Eisenberg (University of 
Pennsylvania)(Hemmi et al. 2000). Myd88-/- mice were provided by Shizuo Akira (Osaka 
University)(Adachi et al. 1998). Myd88-/- were maintained as a breeding colony in our 
facility and were crossed with B6 Thy1.1 and B6 CD45.1 to generate Thy1.1 and CD45.1 
congenic Myd88-/- mice. P14 TCR transgenic mice, which possess CD8 T cells that 
recognize the gp33 epitope of LCMV(Pircher et al. 1989), were provided by Hao Shen 
(University of Pennsylvania) and were crossed to generate Thy1.1 congenic Myd88-/- 
P14 mice.  
Myd88
flox/flox 
mice have been previously described and were provided by Dr. 
Anthony DeFranco (UCSF) and backcrossed at least 7 generations onto the C57BL/6 
background(Hou et al. 2008). R26RYFP reporter mice on a C57BL/6 background were 
provided by Jonathan Maltzman (University of Pennsylvania). R26R
YFP
 mice contain an 
enhanced yellow fluorescent protein (YFP) gene inserted into the Gt(ROSA)26Sor 
locus(Jeong et al. 2004). Expression of YFP is blocked by a loxP-flanked STOP fragment 
placed between the Gt(ROSA)26Sor promoter and the Smo/EYFP sequence(Jeong et al. 
2004). These strains were intercrossed to generate Myd88flox/flox R26RYFP mice, in which 
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expression of Cre-recombinase allows deletion of MyD88 detectable by the YFP reporter. 
CreT2 mice on a C57BL/6 background were provided by Jonathan Maltzman (University 
of Pennsylvania). These mice express a fusion protein of Cre-recombinase fused to a 
mutant estrogen receptor under transcriptional control of the ubiquitin promoter that is 
expressed in all reported tissues(Ruzankina et al. 2007). This CreT2 fusion protein is 
ordinarily restricted to the cytoplasm but can gain access to the nucleus following 
exposure to 4-hydroxytamoxifen. CreT2 mice were crossed with Myd88-/- mice to 
generate Myd88
+/-
 CreT2 mice. These mice were then crossed with Myd88
flox/flox 
R26R
YFP
 
mice to generate Myd88
flox/- 
R26R
YFP
 CreT2 mice and Myd88
flox/+ 
R26R
YFP
 CreT2 
controls. These mice allow tamoxifen-inducible deletion of MyD88, identified by YFP 
expression. Since male CreT2 mice may occasionally express low levels of Cre 
recombinase in germ cells in the absence of tamoxifen treatment (Jonathan Maltzman, 
unpublished observations) we avoided using breeder mice that expressed both the CreT2 
transgene and floxed Myd88 alleles. Thus, our breeding strategy was specifically 
designed so that the CreT2 transgene was only expressed together with the floxed 
MyD88 and R26RYFP reporter genes in experimental and but not in breeder mice. 
Myd88
flox/flox 
mice were also crossed with CD4 Cre mice that express Cre recombinase 
under the control of the CD4 promoter(Lee et al. 2001) to generate mice with a T cell-
specific deletion of MyD88. All colonies were maintained under specific pathogen free 
conditions in accordance with the protocols of the Institutional Animal Care and Use 
Committee of the University of Pennsylvania.  
 Mice were genotyped using DNA isolated from tail clippings or ear clippings. 
Tissues were digested and DNA was purified using either a DNeasy Blood and Tissue Kit 
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(Qiagen) or a REDExtract-N-Amp Tissue PCR Kit (Sigma) according to the 
manufacturers’ instructions. PCR was performed using either PureTaq Ready-to-go PCR 
beads (GE Healthcare) or the REDExtract-N-Amp Tissue PCR Kit (Sigma) according to 
the manufacturers’ instructions. The following PCR primers were used to genotype 
Myd88-/- mice: Myd88 forward 5’ GGT GGT GGT TGT TTC TGA CG 3’, MyD88 
reverse 5’ AAG GCG GGT CCA GAA CCA GG 3’, Neo forward 5’ CGG GAG CGG 
CGA TAC CGT AAA GC 3’, Neo reverse 5’ GCT TGG GTG GAG AGG CTA TTC GG 
3’. The following PCR primers were used to genotype MyD88flox mice: forward: 5’ GTT 
GTG TGT GTC CGA CCG T 3’, reverse: 5’ GTC AGA AAC AAC CAC CAC CAT GC 
3’. The following PCR primers were used to genotype R26R
YFP
 mice: ROSA1: 5’ AAA 
GTC GCT CTG AGT TGT TAT 3’, ROSA2: 5’ GCG AAG AGT TTG TCC TCA ACC 
3’, ROSA3: 5’ GGA GCG GGA GAA ATG GAT ATG 3’. The following PCR primers 
were used to genotype CreT2 mice: hCre forward: 5’ TGG GCG GCA TGG TGC AAG 
TT 3’, hCre reverse: 5’ CGG TGC TAA CCA GCG TTT TC 3’. Expression of the P14 
TCR transgene and CD45 and Thy1 congenic markers was determined by bleeding mice 
and using antibodies against V2 TCR, V8 TCR and the relevant congenic markers to 
phenotype PBMCs by flow cytometry, as described below. 
 
LCMV infection 
Acute LCMV infection was induced by the Armstrong strain of LCMV (LCMV-Arm). 
LCMV was grown, titered and provided by the labs of Hao Shen (University of 
Pennsylvania) and E. John Wherry (The Wistar Institute, PA). Virus stocks were diluted 
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to 4 X 10
5
 P.F.U. in sterile PBS and 2 X 10
5
 PFU were injected per mouse via 
intraperitoneal injection. Secondary re-infection was induced by injecting 2 X 10
6
 PFU of 
LCMV Clone 13 (LCMV-CL13) intravenously into mice that had been infected with 
LCMV-Arm 50-60 days earlier. 
 
In vivo tamoxifen treatment 
Tamoxifen (Sigma) was prepared by mixing in 1g/mL of ethanol. This mixture was then 
diluted to 20mg/mL with corn oil and dissolved by incubating at 37
o
C for several hours 
with constant mixing. To induce deletion, Myd88
flox/- 
and Myd88
flox/+ 
mice were treated 
with 200g tamoxifen/g bodyweight for 5 consecutive days by oral gavage(Park et al. 
2008). Mice were bled 5 days following the last day of treatment and successful treatment 
was confirmed by the presence of YFP+ cells.  
 
Western blotting to verify MyD88 deletion 
MyD88
flox/- 
and MyD88
flox/+
 mice were treated with tamoxifen as indicated above. 5 days 
after the last day of treatment, spleens and lymph nodes were isolated from treated mice 
and untreated controls and stained for flow cytometry as described below. The YFP+ and 
YFP- populations were sorted from total splenocytes, CD4 T cells and CD8 T cells. 
Sorted cells were first lysed at 4°C in lysis buffer composed of 50 mM Tris-HCL (pH 
6.8), 0.2% 2-mercaptoethanol, 20% glycerol, 4% SDS, and 0.001% bromophenol blue 
(Sigma-Aldrich). Cell lysates were clarified by centrifugation at 11,000 g for 10 minutes. 
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Supernatants were boiled for 5 minutes, separated on a 10% SDS-PAGE at 1x10
6 
cell 
equivalents/well and blotted onto Hybond ECL nitrocellulose membranes (Amersham 
Biosciences). Membranes were blocked for 30 minutes in 5% milk in TBST at room 
temperature and then probed with anti-MyD88 antibody (2127, ProSci Inc.) at a 1:500 
dilution in 3% milk in TBST overnight at 4°C. Membranes were washed and probed with 
a horseradish peroxidase–conjugated anti-rabbit secondary antibody at 1:1,000 for 60 
minutes at room temperature. Blots were visualized by enhanced chemiluminescence 
(Roche Diagnostics) according to the manufacturer’s protocol. Antibodies were 
subsequently stripped from membranes using Restore Western Blot Stripping Buffer 
(Pierce Biotechnology) and reprobed as above with an anti-actin antibody at a 1:5000 
dilution.   
 
In vivo 5-bromo-2-deoxyuridine (BrdU) administration 
For short term BrdU pulse (24 hours and under) mice were given an intraperitoneal 
injection of 1mg BrdU (BD Biosciences) every 12 hours. For longer pulses mice were 
given an initial intraperitoneal injection of 1mg BrdU (BD Biosciences) and were then 
given a solution of 1mg/mL BrdU (Sigma) and 1mg/mL dextrose (Sigma) in their 
drinking water. Water bottles were protected from light and changed every 72hrs. To 
detect BrdU incorporation, splenocytes were isolated from treated mice. Following 
staining of surface antigens as described below, cells were fixed, permeabilized and 
stained for BrdU expression using the FITC BrdU flow kit (BD Pharmingen) according 
to the manufacturer’s instructions. 
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Antibodies, flow cytometry and cell sorting 
Single cell suspensions were washed in FACS buffer (PBS + 1% FBS) and stained in 
polystyrene round bottom tubes or in 96-well round bottom plates for 30 minutes at 4
o
C. 
When staining with tetramers, cells were stained for 20 minutes at room temperature. The 
following antibodies were used:  FITC anti-CD44 (IM7), FITC-anti CD69 (H1.2F3), 
FITC anti-CD45R/B220 (RA3-6132), FITC anti-CD19 (1D3), FITC anti-CD4 (RM4-4), 
FITC anti-CD4 (GK1.5), FITC anti-CD8 (53.67), FITC anti-CD3e (17A2), FITC anti-
CD11b (M1/70), FITC anti-CD11c (N418), FITC-anti Gr1/Ly6G (RB6-8C5), FITC anti-
NK1.1 (PK136), FITC anti-TCR (Gl-3), FITC anti- Ly67 (Ter119), FITC anti-CD107a 
(1D4B), FITC anti-CD107b (ABL-93), FITC anti-CD122 (TM-1), FITC anti-KLRG1 
(2F1), FITC anti-V2 TCR (B20-1), FITC anti-BrdU, FITC anti-Bcl-xL (7B2.5), PE 
anti-Annexin V, PE anti 41BB/CD137 (1AH2), PE anti-OX40/CD134 (OX86), PE anti-
ICOS (7E.17G9), PE anti-CD40L/CD154 (MR-1), PE anti-PD1 (J43), PE anti-Fas/CD95 
(MFL3), PE anti-CTLA4/CD152 (UC10-4F10-11), PE anti-CD25 (PC61) PE anti-CD127 
(A7R34), PE anti-V8.1/V8.2 TCR (MR5-2), PE anti-Sca1/Ly-6A/E (E13-161.7), PE 
anti IL-2 (JES6-5H4), PE anti-granzyme B (GB11), PE anti Bcl-2 (3F11), PerCP anti-
CD90.1 (OX7), PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti CD45.2 (104) 
PerCP-Cy5.5 anti-CD127 (A7R34), PerCP anti-CD25 (PC61), APC anti-CD62L (MEL-
14), APC anti-cKit/CD117 (2B8), APC anti-IFN (XMG1.2), APC anti-TNF (MP6-
XT22), PE-Cy7 anti-CD62L (MEL-14), PE-Cy7 anti-CD90.2 (53-2.1), PE-Cy7 anti 
CD45.1 (A20), PE-Cy7 anti IFN (XMG1.2), PE-Cy7 anti PD-1 (RMP1-30), Alexa 
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Fluor® 700 anti-CD4 (L3T4), APC-Alexa Fluor® 750 anti-CD8 (53-6.7), APC-Alexa 
Fluor® 750 anti-CD45.2 (104), APC-Alexa Fluor® 750 anti CD25 (PC61), Pacific 
Blue® anti-CD44 (IM7), Pacific Blue® anti-CD8 (53-6.7) and Pacific Blue® anti IFN 
(XMG1.2). 
All antibodies were purchased from BD Biosciences, eBioscience or Biolegend except 
for KLRG-1 (Beckman Coulter), anti-human Granzyme B (Caltag Laboratories), anti-
Bcl-xL (Southern Biotech). APC conjugated H2-D
b
 gp33, H2-D
b
 np396 and H2-D
b
 
gp276 tetramers were provided by Hao Shen and E. John Wherry.  
  Flow cytometric analysis was primarily performed on a modified FACS Canto 
cytometer with an additional Violet laser (Beckton Dickinson). Some analysis was also 
performed on FACS Calibur and LSR II cytometers (Beckton Dickinson). High speed 
cell sorting was performed on a FACS Aria (Beckton Dickinson). Flow cytometric data 
was analyzed using FlowJo software (Treestar Inc.). 
 
Cell isolations for adoptive transfers and analysis 
Spleens and lymph nodes were pooled from indicated donor mice and single cell 
suspensions were prepared by crushing and filtering through 70M mesh. Red blood cells 
were lysed using ACK lysing buffer (Lonza) and T cells were isolated using negative 
selection MACS T cell isolation kits (Miltenyi Biosciences). Enriched T cells were 
resuspended in HBSS and transferred into recipients via retro-orbital injection. For 
polyclonal T cell transfer experiments 1 X 10
7
 WT or Myd88-/- cells were transferred 
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into B6 Thy1.1 recipients. For P14 cotransfer experiments purified Thy1 congenic WT 
and Myd88-/- T cells were counted and combined at an equal ratio and transferred into 
B6 CD45.1 congenic recipients. To examine T cell responses at the peak of expansion, 
day 7 post infection, 2.5 X 10
4
 combined P14 cells were transferred. To examine early T 
cell proliferation, 1 X 10
6
 combined CFSE-labeled P14 cells were transferred. 
 For progressive analysis of T cell differentiation, 5-6 drops of blood were serially 
collected from infected mice via retro-orbital or sub-mandibular bleeds. Lymphocytes 
were isolated using Histopaque 1083 (Sigma), resuspended in FACS buffer and stained 
with antibodies for flow cytometry as indicated above. For terminal analysis mice were 
sacrificed and spleens and lymph nodes were dissected. In some experiments liver, lung 
and bone marrow were also collected and a peritoneal lavage was performed. Single cell 
suspensions were prepared by crushing tissues and filtering through 70M mesh. Red 
blood cells were lysed using ACK lysing buffer (Lonza) and in the case of cells from 
liver, lung, bone marrow and peritoneal lavage, lymphocytes were enriched using 
Histopaque 1083. Cells were then resuspended in FACS buffer and stained with 
antibodies for flow cytometry as indicated above.  
 
Generation of mixed bone marrow chimeras 
Bone marrow was flushed from femurs and tibias of WT CD45.2 and Myd88-/- CD45.1 
donor mice using a 20 gauge needle. Red blood cells were lysed using ACK lysing buffer 
(Lonza) and T cells were depleted using MACS T cell isolation kits (Miltenyi 
Biosciences). WT and Myd88-/- T cell depleted bone marrow was counted and combined 
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at equal ratio. 1-2 X 10
6
 cells were transferred into lethally irradiated (1000 rads) B6 
CD45.2, Thy1.1 recipients. In some experiments, ACK lysed bone marrow was stained 
with PE Sca1, APC cKit and a FITC lineage cocktail (CD4, CD8, CD3, TCR, CD19, 
B220, NK1.1, CD11b, CD11c, Gr-1, Ter119) and the hematopoietic stem cell-containing 
lineage-, Sca1+, cKit+ (LSK) population was sorted. Equal numbers of WT and Myd88-/- 
LSKs were sorted and 2X10
4
 combined LSKs were transferred into lethally irradiated 
(1000 rads) B6 CD45.1 recipients. 12-16 weeks were allowed for immune reconstitution 
before mice were used for experiments, 
 
Ex vivo restimulation and assessment of T cell effector functions 
Spleens were isolated from mice at the indicated time points following infection and 
single cell suspensions were made as indicated above. LCMV derived peptides were 
provided by Hao Shen and E. John Wherry and included GP33-41, GP61-80, NP396-404 and a 
pooled peptide mixture comprising NP396-404, NP205-212,
 
NP166-175, NP235-243, GP33-41, 
GP276-286, GP118-125, GP92-101,
 
and GP70-77 that accounts for almost all known LCMV 
epitopes(Masopust et al. 2007). 3 X 106 splenocytes were cultured in round bottom plates 
with 0.1g of the indicated LCMV derived peptides in the presence of 0.67L/mL of 
Golgistop (containing monensin, BD Biosciences). In experiments to assess 
degranulation, FITC anti-CD107a and anti-CD107b were also added at the start of 
culture. Cells were harvested after 5-6 hours and surface stained. Cells were then fixed 
and permeabilized using the BD Cytofix/Cytoperm kit according to the manufacturer’s 
instructions. Cells were then stained with PE anti-IL2, APC anti-TNF and PE-Cy7 anti-
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IFN. For granzyme B analysis cells were stained directly ex vivo without any 
restimulation. 
 
Assessing ex vivo T cell survival  
Spleens were isolated from mice at the indicated time points following infection and 
single cell suspensions were made as indicated above. Splenocytes were either examined 
immediately ex vivo or were cultured overnight in RPMI 1640 with or without 10% FBS. 
In experiments to examine whether cytokines could rescue cells from apoptosis, media 
was supplemented with either 100U/mL recombinant mouse IL-2 (R&D Systems) or 
1000U/mL Universal Type-I IFN (PBL Biomedical Laboratories) as indicated. ApoStat 
(FITC-VD-FMK, R&D Systems) was added to cultures for the last 30 minutes of culture 
as per the manufacturer’s instructions to detect total active caspases. After staining of 
surface marker, cells were resuspended in 200L of annxein binding buffer with 4L of 
annexin V PE (BD Pharmingen) and 7mL of the vital dye 7-AAD to assess apoptosis.  
 
In vitro activation-induced cell death (AICD) assay 
Total T cells were MACS purified from spleens and lymph nodes of naïve Myd88-/- 
CD45.2 and congenic WT B6.CD45.1 mice as indicated above. Purified T cells were 
combined at a 1:1 ratio and cultured with 1g/mL plate-bound CD3 and 1g/mL 
soluble CD28 at a density of 3 X 10
6
cells/mL/well in a 24-well plate. 100U/mL of IL-2 
was added to the cells after 24 hours. Following another 24 hours, cells were harvested 
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and live cells were isolated using Histopaque 1083 (Sigma). Live cells were re-plated at a 
density of 1 X 10
6
 per well in a 96 well round bottom plate. Cells were either allowed to 
rest, or were restimulated with either 10g/mL plate-bound CD3, 1g/mL of soluble 
Fas antibody (BD Biosciences), or 50ng/mL recombinant TNF (R&D Systems). Cells 
were harvested at 18, 24 and 48hrs following restimulation. ApoStat (FITC-VD-FMK, 
R&D Systems) was added to cultures for the last 30 minutes of culture as per the 
manufacturer’s instructions to detect total active caspases. After staining of surface 
marker, cells were resuspended in 200L of annxein binding buffer with 4L of annexin 
V PE (BD Pharmingen) and 7mL of the vital dye 7-AAD to assess apoptosis. CD4 and 
CD8 T cells were examined separately during analysis and WT and Myd88-/- cells were 
distinguished on the basis of CD45.1 expression  
 
Assessing the effects of in vitro stimulation of T cells with TLRs 
Naïve (CD44
low
,CD62L
high
,CD25
low
) CD4 or CD8 T cells were FACS purified from 
pooled spleens and lymph nodes of WT or Myd88-/- mice. Sorted T cells were cultured 
with 1g/mL plate-bound CD3 in the presence or absence of 1M CpG-ODN 
(TCCATGACGTTCCTGACGTT) and 1000U/mL murine IFN-1 (PBL Biomedical 
Laboratories) as indicated. After 48 hours, culture supernatants were collected to examine 
levels of secreted IL-2 and IFN by ELISA and cells were washed from plates and lysed 
using lysis buffer composed of 50 mM Tris-HCL (pH 6.8), 0.2% 2-mercaptoethanol, 20% 
glycerol, 4% SDS, and 0.001% bromophenol blue (Sigma-Aldrich). Cell lysates were 
separated on a 10% SDS-PAGE at 1x10
6 
cell equivalents/well and blotted onto Hybond 
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ECL nitrocellulose membranes (Amersham Biosciences) as indicated above. Blots were 
probed with a rabbit anti-Bcl-xL antibody (Cell Signaling) followed by a horseradish 
peroxidase–conjugated anti-rabbit secondary. Following visualization, antibodies were 
stripped and blots were reprobed as above with an anti-actin antibody.   
 
Examining naïve T cell responses to Type I IFNs 
CD8 T cells were MACs purified from WT or Myd88-/- mice as indicated above. To 
examine proximal signaling in response to stimulation with Type I IFNs, purified T cells 
were either rested or stimulated with 1g/mL plate-bound CD3 for 24hrs. Cells were 
then culture for 30 minutes in the presence or absence of 10000U/mL of murine IFN1 
or 1000U/mL Universal Type-I IFN (PBL Biomedical Laboratories) as indicated in 
figures. Cells were then lysed and lysates were separated on a 10% SDS-PAGE at 1x10
6 
cell equivalents/well and blotted onto Hybond ECL nitrocellulose membranes as 
indicated above. Blots were probed using a rabbit anti-phosphpo-STAT 3 antibody (Cell 
Signaling) followed by a horseradish peroxidase–conjugated anti-rabbit secondary. After 
visualization, antibodies were stripped and blots were reprobed as above using a rabbit 
anti-phospho-STAT 1 antibody (Cell Signaling). Antibodies were once again stripped 
and blots were reprobed using an anti-actin antibody.   
To examine longer-term effects of Type-I IFNs, MACs purified WT or Myd88-/- CD8 T 
cells were cultured for 72hrs with 0.3g/mL or plate-bound CD3 and 2.5g/mL plate-
bound CD28 in the presence or absence of 10-1000U/mL Universal Type-I IFN (PBL 
Biomedical Laboratories) or 5ng/mL IL-12 (R&D Systems). Following 72hrs of culture, 
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cells were either stained with Annexin-V and 7AAD to assess viability, or were fixed and 
permeabilized to examine levels of granzyme B and IFN by intracellular staining. 
 
Quantitative PCR for apoptotic markers 
Adoptively transferred WT and Myd88-/- P14 cells were sorted from recipients 4 days 
after LCMV infection by FACS on the basis of congenic markers. RNA was purified 
from the sorted cells using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. RNA was subsequently repurified and concentrated using the 
RNeasy MinElute Cleanup Kit (Qiagen). RNA concentration and purity was measured on 
the basis of absorption at 260nm and 280nm using a spectrophotometer. Equal amounts 
of RNA were converted to cDNA using a RT
2
 First Strand Kit (SA Biosciences) and then 
used in a Mouse Apoptosis PCR Array (stock # PAMM-012, SA Biosciences) according 
to the manufacturer’s instructions. Amplification was performed using an ABI Prism 
7000 thermocycler (Applied Biosystems) and analyzed using ABI Prism 7000 SDS 
software (Applied Biosystems). Ct was calculated and normalized to the average Ct of 
the housekeeping genes, actin, Gapdh and Hprt1. Normalized Ct of Myd88-/- and WT 
test samples were then compared and expressed as a relative fold difference of Myd88-/- 
P14/ WT P14. 
 
Full genome microarray  
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Adoptively transferred WT and Myd88-/- P14 cells were sorted and pooled from 20 
recipients 5 days after LCMV infection by FACS on the basis of congenic markers. RNA 
was purified from the sorted cells using the RNeasy Mini Kit (Qiagen) and subsequently 
repurified and concentrated using the RNeasy MinElute Cleanup Kit (Qiagen) according 
to the manufacturer’s instructions. RNA samples were given to the Functional Genomics 
Core of the Diabetes and Endocrinology Research Center (University of Pennsylvania) 
for subsequent processing. Functional Genomics Core staff verified RNA integrity using 
an Agilent Bioanalyzer and performed a two-color Agilent microarray. WT and Myd88-/- 
RNA samples were divided to perform mircoarrays in technical triplicates. Data were 
filtered and normalized prior to calculation of fold-changes. The significance of fold-
changes was assessed by comparing them to the variation in each gene across triplicates 
using permutation tests. A fold-change of 1.5 or greater was used as a cutoff to generate a 
list of differentially expressed genes. The gene lists that were over-expressed and under-
expressed in Myd88-/- relative to WT P14 cells were then processed separately using the 
Database for Annotation, Visualization, and Integrated Discovery (DAVID, NIH) to 
generate functional annotation clusters(Dennis et al. 2003). Significance of associations 
was determined based on the EASE score, a modified Fisher Exact P-value for gene 
enrichment analysis. 
 
Statistical analysis 
A Student’s t-test was used to determine the statistical significance of differences 
between data sets where indicated. A p value of less than 0.05 was considered significant. 
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CHAPTER 3: MyD88 plays a T cell intrinsic role in controlling 
primary CD8 T cell expansion during acute LCMV infection 
 
Introduction 
Lymphocytic choriomeningitis virus (LCMV) is the prototypic murine arenavirus 
and is a natural mouse pathogen that has been extensively characterized as a viral 
infection model. LCMV infection of adult mice can result in different outcomes 
depending on the strain of the virus, the dose and route of infection and the background 
strain of the host. The Armstrong strain of LCMV induces an acute infection in B6 mice 
that elicits a dramatic expansion of CD8 T cells that play an important role in viral 
clearance.  A recent study has found that LCMV-specific effector cells divide at least 15 
times and comprise over 80% of CD8 T cell pool at the peak of the response, 8 days after 
infection(Masopust et al. 2007).  
LCMV infection has routinely been employed to study adaptive immune 
responses to viral infection and numerous reagents have been developed that allow the 
analysis of T cell responses at the single cell level. The LCMV genome encodes a total of 
4 proteins and examination of the nucleoprotein and glycoprotein sequences revealed 
several potential CD8 T cell epitopes in B6 mice. This has resulted in the generation of 
arrays of LCMV-derived peptides which, when coupled with intracellular cytokine 
staining, can be used to examine effector cytokine production in response to specific viral 
epitopes. More recently, MHC class I tetramers have been developed that allow antigen 
specific CD8 T cells to be enumerated in the absence of a functional readout. 
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Furthermore, a TCR that recognizes the gp33 epitope of LCMV in the context of H2-D
b
 
has been cloned and used to generate the P14 TCR transgenic mouse(Pircher et al. 1989). 
Together, these tools make LCMV an ideal model for examining in vivo T cell responses 
to a natural, viral pathogen. 
Myd88-/- mice have been shown to develop a greatly reduced frequency of 
antigen-specific effector CD8 T cells following LCMV infection. This results in reduced 
cytokine production and cytolytic activity, which is associated with impaired viral 
clearance of LCMV-WE and high dose LCMV-Armstrong(Zhou et al. 2005). Similarly, the 
spleens of mice lacking IRAK-4, the signaling kinase downstream of MyD88, have also 
been found to contain fewer CD8 T cells following LCMV infection resulting in reduced 
cytolytic activity and impaired viral clearance(Lye et al. 2008). Together, these studies 
indicate an important role for TLR signaling pathways in controlling T cell responses to 
LCMV.  
In response to LCMV infection, Myd88-/- mice produce significantly lower levels 
of pro-inflammatory cytokines, consistent with the importance of MyD88 in the innate 
immune response. In particular, plasmacytoid dendritic cells in Myd88-/- mice produce 
lower levels of Type I IFNs which, in turn, have been shown to play an important role in 
promoting T cell expansion. Antigen presentation of LCMV-derived peptides may also 
be impaired. Together, these defects in the innate immune response may be expected to 
contribute greatly to the impaired adaptive immune response to LCMV in Myd88-/- mice 
described earlier. However, in light of the studies discussed in Chapter 1, which 
demonstrated that MyD88-dependent pathways can regulate T cell responses in vitro, I 
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wanted to examine whether the impaired T cell response also reflects a direct role for 
MyD88 in T cells during LCMV infection. In the following sections we directly examine 
the importance of T-cell intrinsic MyD88 expression during naïve T cell differentiation, 
proliferation and survival during the phase of clonal expansion following acute LCMV 
infection. 
 
3.1 Myd88-/- mice mount greatly reduced T cell responses to LCMV  
Infection of C57BL/6 (WT) mice with LCMV-Armstrong induces a dramatic expansion 
of CD8 T cells peaking 8 days post infection. Consistent with earlier reports we found 
greatly reduced CD8 T cell numbers in the spleens of Myd88-/- mice following LCMV 
infection (Fig. 3.1A). Notably, the difference in cell numbers was restricted to cells that 
expressed high levels of CD44, characteristic of antigen experienced cells.  
To further characterize these defects we next used available reagents to 
specifically examine antigen-specific T cells. We found a greatly reduced frequency of 
antigen-specific IFN-producing CD8 T cells in Myd88-/- splenocytes following an ex 
vivo restimulation with H-2D
b
 restricted LCMV-derived peptides (Fig 3.1B). Similarly, 
we found a reduced frequency of IFN-producing CD4 T cells in response to stimulation 
with the I-A
b
-restricted gp61-80 peptide (Fig 3.1B). While these findings appeared to 
indicate a reduced frequency of antigen-specific cells it could also potentially reflect a 
failure of antigen specific cells in Myd88-/- mice to differentiate into cytokine-producing 
effector cells. To distinguish between these possibilities we used MHC class I tetramers 
to enumerate CD8 T cells specific for known immunodominant LCMV epitopes 
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independent of their functional responses. We found a greatly reduced percentage (Fig 
3.1C) and absolute number (Fig 3.1D) of antigen specific cells in Myd88-/- mice.  
These findings suggest that the absence of IFN producing cells primarily reflects 
a reduced frequency of LCMV-specific CD8 T cells at the peak of the response. 
However, it should be noted that the relative difference in the frequency of tetramer-
specific cells between WT and Myd88-/- mice (Fig 3.1C) appears to be somewhat less 
than the difference in the frequency of IFN producing cells (Fig 3.1B), suggesting that 
MyD88 may also contribute to the development of T cell effector functions. In addition 
to their reduced number, we also observed differences in phenotypic receptor expression 
on LCMV-specific CD8 T cells from Myd88-/- mice. In particular, we found significantly 
elevated levels of the inhibitory receptor PD-1 on Myd88-/- CD8 T cells, most notably 
within the np396-specific population (Fig 3.1E). This complements the results of a recent 
study that found that concurrent TLR stimulation promoted lower levels of PD-1 
expression on CD8 T cells following peptide vaccination(Wong et al. 2009). Notably, we 
found that these elevated levels of PD-1 appeared to be correlated with a more dramatic 
reduction in the np396-specific population of T cells in Myd88-/- mice than the gp33 or 
gp276-specific populations, suggesting that MyD88 expression regulates the pattern of 
immunodominance in the T cell response. Overall, these findings suggest that MyD88 
appears to control the frequency, function and phenotype of LCMV-specific T cells 
following infection.     
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3.2 The importance of MyD88 in LCMV cannot be attributed to individual TLR 
pathways 
Given that MyD88 is required for signaling through multiple TLR pathways we wished 
to examine whether the phenotype of Myd88-/- mice following LCMV infection could be 
recapitulated in mice lacking specific MyD88-dependent receptors. As discussed earlier, 
B6 T cells have been shown to respond directly to ligands for TLR2 and TLR9 in vitro. 
We therefore infected Tlr2-/- and Tlr9-/- mice to determine whether T cell responses to 
LCMV are impaired in the absence of these TLR pathways. In contrast to the severely 
impaired T cell response in Myd88-/- mice, we found no significant reduction in the 
frequency (Fig 3.2A) or total number (Fig 3.2B) of antigen specific CD8 T cells in the 
spleens of Tlr2-/- or Tlr9-/- mice following LCMV infection. In fact, Tlr2-/- splenocytes 
showed an increased frequency of CD8 T cells and an increased frequency of tetramer-
specific cells within the CD8 T cell population resulting in a significantly greater overall 
number of tetramer-specific cells than WT mice (p = 0.02) (Fig 3.2B). CD8 T cells from 
Tlr2-/- and Tlr9-/- mice also produced IFN following ex vivo restimulation with LCMV-
derived peptides suggesting that the absence of these TLR pathways does not impair CD8 
T cell expansion or effector differentiation (Fig 3.2C). These findings are supported by a 
recent study that also found that the phenotype of Myd88-/- mice was not recapitulated in 
mice lacking individual TLR pathways(Jung et al. 2008).  
In addition to TLR signaling, MyD88 also plays a role in signaling downstream of 
the IL-1R family. Cytokines in this family, including IL-1 and IL-18, have been shown to 
play a role in controlling T cell survival and effector differentiation(Adachi et al. 1998)(Li et 
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al. 2007)(Denton et al. 2007). We therefore examined T cell responses following LCMV 
infection in IL1r-/- and IL18r-/- mice to see whether these pathways, rather than TLRs 
may account for the importance of MyD88. We found no reduction in the frequency (Fig. 
3.2A) or number (Fig 3.2B) of antigen specific CD8 T cells in IL1r-/- mice, and while 
there were significantly fewer tetramer-specific CD8 T cells in the spleens of IL18r-/- 
mice (p = 0.03), the CD8 T cell response was far larger than observed in Myd88-/- mice. 
Furthermore, CD8 T cells from IL1r-/- and IL18r-/- produced IFN upon ex vivo 
restimulation (Fig 3.2C) suggesting that these pathways are also dispensable for effector 
differentiation. Together, these results suggest that the impaired T cell response to LCMV 
infection in Myd88-/- mice cannot be narrowed down to the role of specific MyD88-
dependent receptors. In light of this finding, we decided to continue to focus on Myd88-/- 
cells for subsequent studies. 
 
3.3 Adoptively transferred WT T cells expand better than endogenous T cells in 
Myd88-/- hosts 
We have showed that MyD88 plays an important role in controlling T cell responses 
following LCMV infection, but it was unclear whether this reflected a direct or indirect 
role in T cells. As discussed earlier, the reduced levels of type I IFNs and other pro-
inflammatory cytokines in Myd88-/- mice during LCMV infection suggest that the 
MyD88-deficient innate immune compartment may not effectively support T cell 
expansion and effector differentiation(Jung et al. 2008). However, given that MyD88-
dependent pathways can also directly regulate T cell functions, the impaired T cell 
38 
 
response in Myd88-/- mice could potentially reflect an intrinsic role for MyD88 in T cells 
during LCMV infection.  
To examine the relative contribution of MyD88 in the innate immune 
compartment, we transferred naïve WT CD8 T cells were into congenic, Myd88-/- 
recipients, which were then infected with LCMV (Fig 3.3A). We found that adoptively 
transferred WT CD8 T cells mounted a reduced response to LCMV infection in Myd88-/- 
hosts compared to their response in WT controls, resulting in 2-fold fewer transferred 
cells 8 days after infection (Fig 3.3B). This corresponded to a significantly reduced 
frequency (Fig 3.3C) and number (Fig 3.3D) of antigen-specific, IFN-producing cells. 
Notably, there was a greater reduction in the np396-responsive population than in the 
gp33-responsive population suggesting that MyD88 in the host environment contributes 
to the pattern of immunodominance in the T cell response.  
The reduced frequency of IFN producing cells correlated with a reduced 
frequency of LCMV-specific cells as identified by tetramer staining (Fig 3.3E), 
indicating reduced expansion rather than a failure to differentiate into IFN-producing 
effectors. Further examination of the phenotype of these tetramer-specific cells revealed 
that WT T cells expressed higher levels of PD-1 in Myd88-/- hosts than in WT controls 
(Fig 3.3F). This suggests that the elevated levels of PD-1 observed in Myd88-/- mice (Fig 
3.1F) are primarily associated with the MyD88-deficient environment rather than an 
intrinsic characteristic of the T cells. 
Importantly however, while the donor WT T cells did not expand as greatly in 
Myd88-/- hosts as in WT hosts, they expanded far better than the endogenous Myd88-/- 
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CD8 T cells as indicated by a greater relative percentage of tetramer-specific cells than 
the endogenous Myd88-/- cells (Fig 3.3F). Therefore, while these results support earlier 
studies suggesting that MyD88 plays an important, T cell-extrinsic role in supporting T 
cell responses during LCMV infection, the absence of MyD88 in the host environment 
does not entirely account for the reduced CD8 T cell response in Myd88-/- mice. This 
suggests that the importance of MyD88 during LCMV infection may be attributable to 
both T cell-extrinsic and T cell-intrinsic components. 
 
3.4 Myd88-/- T cells fail to expand effectively when transferred to WT hosts 
To more directly examine the potential contribution of MyD88 in T cells during LCMV 
infection, we performed the reciprocal adoptive transfer of purified CD8 T cells from 
naïve Myd88-/- mice into congenic WT recipients (Fig 3.4A). Despite the provision of a 
WT APC compartment and pro-inflammatory cytokine milieu, we found that Myd88-/- 
donor CD8 T cells did not expand as effectively as WT CD8 T cells in response to 
LCMV, resulting in approximately 10-fold fewer donor cells 8 days after infection (Fig 
3.4B). While the Myd88-/- donor population generated antigen-specific IFN-producing 
effector cells, their frequency (Fig 3.4C) and overall number (Fig 3.4D) were 
dramatically reduced. This also corresponded to a greatly reduced frequency of antigen 
specific cells as detected by tetramer staining (Fig 3.4E), suggesting that MyD88 
intrinsically regulates LCMV-specific T cell expansion rather than the development of 
effector functions.  
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When comparing these findings to our results in Fig. 3.3 it is striking to note that 
the reduced expansion of Myd88-/- CD8 T cells in WT hosts is far more dramatic than the 
reduced expansion of WT CD8 T cells in Myd88-/- hosts following LCMV infection. 
Together, these reciprocal transfer experiments suggest that the T cell-intrinsic 
expression of MyD88 is critical in regulating T cell expansion and is an essential 
consideration in accounting for the reduced T cell responses observed in Myd88-/- mice. 
 
3.5 The impaired LCMV response of Myd88-/- T cells does not result from a 
developmental defect in a Myd88-/- environment 
These adoptive transfer experiments indicate a T cell-intrinsic role for MyD88 during 
acute LCMV infection. However, it was possible that T cell development in a MyD88-
deficient environment could cause persistent functional impairments, resulting in 
diminished expansion of Myd88-/- LCMV-specific CD8 T cells despite transfer into a 
WT environment. To address this potential issue we sorted the hematopoietic stem cell-
containing LSK populations from the bone marrow of Myd88-/- and Myd88+/+ 
littermates, combined them with congenically disparate WT LSKs and transferred them 
into lethally irradiated recipients to generate WT/KO and WT/WT chimeras (Fig 3.5A). 
These mixed bone marrow chimeras allowed us to examine the responses of WT and 
Myd88-/- T cells that developed together in the same mouse. 
 We found that WT and Myd88-/- hematopoietic stem cells had repopulated the 
hematopoietic compartment comparably by 16 weeks post transplant. Thus, the CD8 T 
cell compartment contained an equivalent proportion of CD45.1 and CD45.2 cells in both 
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WT/KO and WT/WT uninfected chimeras (Fig 3.5B and C). We found a similar 
proportion of CD45.1 and CD45.2 cells in the CD4 T cell compartment of uninfected 
chimeras. Following LCMV infection, however, we found that the Myd88-/- fraction of 
the CD8 T cell compartment did not expand as effectively as the WT compartment, 
resulting in a significant decrease in the relative proportion of Myd88-/- CD8 T cells in 
WT/KO chimeras (Fig 3.5 B and C). Notably, overall T cell expansion following 
infection was comparable in WT/KO and WT/WT chimeras (Fig 3.5C), suggesting that 
the absence of MyD88 in half of the innate immune compartment did not significantly 
impair the ability of the innate immune system to support T cell responses to LCMV.  
The reduced expansion of the Myd88-/- T cell compartment WT/KO chimeras 
corresponded to a lower frequency of LCMV-specific CD8 T cells as identified by 
tetramers (Fig 3.5D). However, despite their reduced frequency, LCMV-specific Myd88-
/- CD8 T cells expressed comparable levels of PD-1 as WT cells (Fig 3.5E) and also 
produced IFN in response to restimulation with H2-D
b
 restricted LCMV derived 
peptides (Fig 3.5F). These findings indicate, consistent with our earlier results, that 
MyD88 regulates CD8 T cell expansion but not differentiation into functional effectors. 
Notably, restimulation with the I-A
b
 restricted gp61-80 peptide showed a reduced 
frequency of LCMV-specific CD4 T cells in the Myd88-/- compartment of WT/KO 
chimeras (Fig 3.5F), suggesting that MyD88 intrinsically regulates both CD8 and CD4 T 
cell expansion following LCMV infection. 
  
3.6 Myd88-/- P14 transgenic T cells do not expand as effectively as WT P14 cells 
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The results thus far show that MyD88 plays a T cell-intrinsic role in regulating T cell 
expansion in response to LCMV infection. Since these experiments examined naturally 
occurring LCMV-specific T cell clones in a polyclonal response, it remained possible 
that T cell population developed differences in its TCR repertoire in the absence of 
MyD88, which subsequently influenced its response to infection. To circumvent potential 
repertoire differences in the polyclonal Myd88-/- T cell population, we crossed Myd88-/- 
mice with P14-TCR transgenic mice, whose T cells recognize the LCMV-derived gp33-
41 epitope. By further crossing these mice onto congenic backgrounds we were able to 
isolate WT and Myd88-/- P14 cells that could be distinguished on the basis of 
Thy1.1/Thy1/2 disparity. Combining these cells and co-transferring them into congenic 
WT recipients allowed us to directly compare the responses of a monoclonal population 
of WT and Myd88-/- cells within the same mouse (Fig 3.6A). 
 The adoptively transferred P14 population expanded dramatically in response to 
LCMV infection, but there were 10-fold more WT than Myd88-/- P14 cells in the spleens 
of mice at the peak of the response (Fig 3.6B), consistent with the reduced expansion in 
the polyclonal Myd88-/- T cell repertoire. We wanted to confirm that the reduced number 
of Myd88-/- P14 cells in the spleens of infected mice did not reflect their sequestration in 
other tissues. Although we noted some differences in their relative tissue distributions, 
the percentage of Myd88-/-, relative to WT, P14 cells was also reduced in the peripheral 
lymph nodes, peritoneum and liver of infected mice, suggesting that their reduced 
numbers truly reflected reduced expansion rather than differential trafficking.  
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3.7 Myd88-/- P14 T cells develop effector phenotype and functions following LCMV 
infection.  
The ability to clearly distinguish the transferred P14 cells of congenic markers allowed us 
to examine whether the reduced expansion of the Myd88-/- cells was associated with 
differences in their effector phenotype or functions. We found no differences in the 
expression of the T cell costimulatory receptors 41-BB, OX-40, ICOS, CD27 or CD40L 
(Fig 3.7A). Similarly, we found no differences in the expression of inhibitory receptors 
PD-1, Fas, or CTLA-4 (Fig 3.7B) or the cytokine receptors CD25, CD127 or CD122 (Fig 
3.7C). These results suggest that the reduced expansion of Myd88-/- P14 cells is not a 
secondary effect of reduced costimulation or cytokine signaling. We also found that 
Myd88-/- P14 cells upregulated granzyme B expression and produced IFN and TNF 
comparably to WT P14 cells (Fig 3.7D). Thus, consistent with our earlier results with 
polyclonal T cell adoptive transfer and mixed bone marrow chimeras, MyD88 appears to 
intrinsically regulate CD8 T cell expansion following LCMV infection but not 
differentiation into functional effectors. 
 
3.8 Myd88-/- T cells proliferate comparably to WT T cells in response to LCMV but 
fail to accumulate. 
Our results thus far show greatly reduced clonal expansion of Myd88-/- CD8 T cell in 
response to LCMV. T cell numbers at peak expansion reflect the combined effects of 
proliferation and cell survival, thus we sought to examine which of these processes 
involved MyD88. At the peak of the response, the majority of the CD8 T cell population 
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in WT mice is comprised of rapidly cycling effector cells, a large proportion of which 
incorporate BrdU during a 24 hour labeling period. In contrast, only a small proportion of 
the CD8 T cells in Myd88-/- mice incorporated BrdU, consistent with a reduced 
frequency of rapidly expanding effector T cells (Fig. 3.8A). This was consistent with the 
reduced proportion of LCMV-specific effectors in the CD8 T cell population of Myd88-/- 
mice (Fig. 3.1). However, examination of the tetramer-specific cells revealed that the 
small population of LCMV-specific Myd88-/- CD8 T cells incorporated BrdU 
comparably to WT CD8 T cells (Fig. 3.8B). This suggested that LCMV-specific T cells 
in Myd88-/- mice proliferated at a normal rate, implying that their dramatically lower 
numbers reflect impaired survival. 
To more comprehensively examine cell proliferation, we co-transferred CFSE-
labeled WT and Myd88-/- P14 cells into congenic hosts to examine early proliferation in 
response to LCMV infection. No spontaneous proliferation was observed upon transfer, 
since both WT and Myd88-/- P14 cells remained CFSE
high
 in uninfected recipients (Fig. 
3.8C). At 72hrs following LCMV infection, both WT and Myd88-/- P14 cells proliferated 
rapidly and underwent multiple rounds of division, diluting CFSE beyond the level of 
detection by 96hrs, suggesting that WT and Myd88-/- P14 cells proliferate comparably in 
response to LCMV. While division profiles appeared similar, the relative proportion of 
Myd88-/- to WT P14 cells decreased over time, corresponding to reduced accumulation 
of Myd88-/- T cells (Fig 3.8C and 3.8D). The reduced numbers of Myd88-/- P14 cells 
became most apparent by day 4 post infection, at which point proliferation could no 
longer be resolved by CFSE dilution. As it was possible that Myd88-/- T cells proliferated 
normally for the first 7-8 rounds of division but subsequently stopped proliferating earlier 
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than WT T cells, we used BrdU to compare the proportion of transferred WT and Myd88-
/- P14 cells that were actively cycling at later time points. We found that a similar 
percentage of the adoptively transferred WT and Myd88-/- P14 cells incorporated BrdU 
during a 12hr labeling period on days 4, 5 and 6 following LCMV infection (Fig 3.8E). 
Thus, the capacity for proliferation between the two populations appeared to be similar 
throughout the period during which the number of WT P14 cells greatly exceeded the 
number of Myd88-/- P14 cells.  
 
3.9 Antigen specific Myd88-/- T cells from LCMV infected mice exhibit increased 
spontaneous apoptosis. 
Reduced accumulation of LCMV-specific Myd88-/- T cells despite comparable 
proliferation indicated reduced survival. To directly examine the survival of transferred 
Myd88-/- and WT P14 cells following LCMV infection, we compared their viability 
using light scatter properties, annxein V staining and caspase activation. Surprisingly, we 
observed no significant differences in the viability of WT and Myd88-/- P14 cells directly 
ex vivo at any of the time points examined (Fig 3.9A, left panels and data not shown). 
Since this could potentially reflect the rapid clearance of apoptotic cells in vivo, we 
isolated splenocytes from infected recipients during the period of T cell expansion and 
cultured them ex vivo. Following 20hrs of culture ex vivo we found significantly reduced 
survival of the Myd88-/- P14 cell (Fig 3.9A right panels). This reduced survival resulted 
in a decline in the relative ratio of live Myd88-/- to WT P14 cells during the culture 
period, consistent with the reduced accumulation of Myd88-/- P14 cells seen in vivo. 
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Together, these data indicate that the reduced number of Myd88-/- T cells following 
LCMV infection primarily reflects impaired survival, rather than impaired proliferation. 
 
3.10 Myd88-/- P14 cells do not exhibit differences in the survival molecules Bcl-xL, 
Bcl-2 or Bim. 
The in vitro studies described earlier showed that TLR ligands can act directly on T cells 
to increase survival through upregulation of the anti-apoptotic protein, Bcl-xL(Gelman et 
al. 2004)(Cottalorda et al. 2006). We therefore hypothesized that the reduced survival of 
Myd88-/- CD8 T cells following LCMV infection may be associated with reduced levels 
of Bcl-xL. However, we did not find significant differences in the expression of the Bcl-
xL between WT or Myd88-/- P14 cells by intracellular staining (fig. 3.10A). Recent 
reports have also demonstrated that T cell survival and contraction following LCMV 
infection are regulated by the anti-apoptotic molecule Bcl-2 and the pro-apoptotic BH3 
only protein, Bim(Wojciechowski et al. 2006)(Wojciechowski et al. 2007). We therefore also 
examined the levels of these molecules but did not find significant differences in their 
expression between WT and Myd88-/- P14 cells (fig 3.10A). 
 Since the resolution offered by intracellular cytokine staining may not be 
adequate to detect more subtle differences in the level of expression of these apoptotic 
proteins we also decided to examine their RNA expression using real-time, quantitative 
PCR. We sorted WT and Myd88-/- P14 cells from infected recipients 4 days after 
infection and examined the expression of multiple apoptosis-related genes using an 
apoptosis PCR array. Using this assay we found no notable differences between WT and 
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Myd88-/- P14 cells in the expression of Bcl-2, Bcl-xL or in other pro and anti-apoptotic 
Bcl-2 family members (Fig. 3.10B). It should be noted however, that the RNA yields 
from the sorted cells were in the lower end of the range recommended to be used in these 
PCR arrays, which potentially reduces the sensitivity of the assay. 
 
3.11 WT and Myd88-/- T cells are comparably sensitive to Fas induced cell death. 
We have already shown that the reduced expansion of Myd88-/- T cells following LCMV 
infection is not observed in mice lacking individual MyD88-dependent TLR or cytokine 
receptors (Section 3.2). While this could potentially reflect the redundancy of multiple 
TLR or cytokine pathways during in vivo immune responses, we also considered that the 
importance of MyD88 during LCMV infection might be related to a role in alternative 
signaling pathways.  As discussed earlier, MyD88 has been shown to participate in Fas-
induced signaling pathways in macrophages and fibroblasts due to its ability to interact 
with other death domain containing proteins. It has been shown that, as a result of these 
homotypic death-domain interactions, the expression of FADD can inhibit signaling 
through TLRs by sequestering MyD88 away from TLR signaling pathways(Zhande et al. 
2007). We therefore hypothesized that the expression of MyD88 and its interaction with 
FADD may reciprocally inhibit signaling through Fas, thereby potentially rendering 
Myd88-/- T cell hyperesponsive to Fas induced apoptosis. Fas has recently been shown to 
contribute to the contraction of the CD8 T cell response following LCMV infection, 
suggesting that Fas-signaling is a potentially relevant pathway of apoptosis in LCMV-
specific T cells(Zhou et al. 2002)(L. T. Nguyen et al. 2000)(Weant et al. 2008). TNF-induced 
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signaling has been shown to play a role in down-regulating the CD8 T cell response 
following LCMV infection(Nguyen et al. 2000)(Singh & Suresh 2007) and signals 
downstream of the TNFRs also involve death domain-containing proteins(Hsu et al. 
1995)(Micheau & Tschopp 2003), raising the potential for interactions with MyD88. While 
we had already found that Fas expression was comparable between WT and Myd88-/- 
P14 T cells following infection (fig. 3.7B), this did not address potential differences in 
signaling downstream of the Fas receptors. We therefore hypothesized that enhanced 
signaling through Fas or TNF pathways may account for the increased apoptosis of 
Myd88-/- T cells following LCMV infection.  
Naïve T cells upregulate Fas expression in response to TCR-induced activation in 
the presence of IL-2(Refaeli et al. 1998). Following restimulation, these recently activated 
T cell undergo Fas-mediated apoptosis in a process termed activation induced cell death 
(AICD) (Van Parijs et al. 1996)(Refaeli et al. 1998). We therefore employed an in vitro AICD 
assay to directly compare the susceptibility of WT and Myd88-/- T cells to Fas-induced 
cell death. We used a coculture system of congenically marked cells so that WT and 
Myd88-/- T cells would be exposed to identical stimuli throughout the experiment. Using 
this assay, we found no differences in AICD of WT and Myd88-/- CD4 or CD8 T cells 
following restimulation with high-doses of anti-CD3 antibody, as assessed by both 
Annexin V staining and the detection of activate caspases (Fig 3.11A). To address the 
potential caveat that TCR induced AICD was not occurring through Fas, we also 
stimulated activated cells with anti-Fas antibody or recombinant TNF to directly induce 
Fas or TNFR-induced cell death. Consistent with our results with TCR-induced AICD, 
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we found no differences in apoptosis or caspase activation between WT and Myd88-/- 
cells (Fig 3.11A). These results show that WT and Myd88-/- T cells are comparably 
susceptible to Fas and TNF induced apoptosis, suggesting that enhanced signaling 
through these pathways does not account for the increased apoptosis of Myd88-/- T cells 
following LCMV infection. 
 
3.12 WT and Myd88-/- T cells show comparable responses to Type I IFNs 
Our results suggests that the importance of MyD88 in supporting T cell survival during 
LCMV infection may not be related to its traditional role in TLR or IL1R family cytokine 
signaling, or to a role in Fas or TNFR signaling. In considering other potential roles for 
MyD88 in T cells, we noted that the phenotype of Myd88-/- CD8 T cells following 
LCMV infection was strikingly similar to that of T cells lacking the type I IFN receptor. 
Similarly to Myd88-/- P14 cells, in comparison to WT P14 cells, IFNR-/- P14 cells have 
been found to undergo increased apoptosis during LCMV infection, which results in 
greatly diminished expansion despite comparable proliferation(Kolumam et al. 
2005)(Aichele et al. 2006). Given these similarities, we considered whether MyD88 may be 
playing a role in IFN-induced signaling pathways in T cells. 
 As discussed earlier, MyD88-dependent signals have been shown to play an 
important role in the induction of Type-I IFN production in APCs through the 
recruitment of IRF1, 5 and 7(Takaoka et al. 2005)(Honda et al. 2004). However, a role of 
MyD88 downstream of signaling through IFN-IR is less clear. A recent study found that 
IFN treatment enhanced human B cell responses to TLR9 stimulation through 
50 
 
upregulation of MyD88 expression(Giordani et al. 2009). We therefore considered whether 
an element of the IFN-I induced survival program in LCMV-specific T cells occurred as 
a result of increased signaling through a MyD88-dependent signaling pathway. To test 
this possibility we examined whether IFN, in analogy to B cells, promotes enhanced 
signaling through MyD88-dependent TLR pathways in T cells. As discussed earlier, 
treatment of TCR-activated CD4 and CD8 T cells with ligands for TLR2 and TLR9 
promotes enhanced survival associated with Bcl-xL upregulation(Gelman et al. 
2004)(Cottalorda et al. 2006). Using Bcl-xL upregulation as a readout for T cell responses 
to TLR stimulation, we found that IFN did not appreciably enhance MyD88-dependent 
signaling in T cells (Fig 3.12A).  
 While it did not appear that IFN enhanced MyD88-dependent, TLR-induced 
signaling in T cells, we considered the reciprocal possibility that MyD88 may play a role 
in supporting IFNR-induced signals. TLR stimulation has been shown to induce STAT1 
phosphorylation in macrophages through a MyD88-dependent mechanism(Toshchakov et 
al. 2002)(Rhee et al. 2003). However, we found that Myd88-/- and WT T cells comparably 
phosphorylated STAT1 in response to stimulation with IFN, suggesting that MyD88 is 
not required for STAT1 phosphorylation in T cells (Fig 3.12B). Since the pro-survival 
effects of IFN-induced signaling in T cells have been attributed to STAT3 
signaling(Tanabe et al. 2005) we also examined this pathway and found that Myd88-/- T 
cells similarly did not have a defect in STAT3 phosphorylation following IFN 
stimulation (Fig 3.12B).  
51 
 
These experiments suggested that Myd88-/- T cells did not have a defect in 
inducing proximal signals in response to IFN, but did not rule out a potential role for 
MyD88 in regulating IFN-induced signals further downstream. To address this issue, we 
compared longer term responses of WT and Myd88-/- T cells to IFN-stimulation. 
Consistent with earlier reports(Curtsinger et al. 2005), we found that IFN-I and IL-12 
promoted increased survival and granzyme B upregulation during in vitro CD8 T cell 
activation and we found no reduction in these responses in Myd88-/- T cells (Fig. 3.12C). 
While these results suggested that MyD88 was not required for type I IFN signaling in T 
cells, we also considered the possibility that MyD88 may play a role in IFN-signaling 
specifically in LCMV-specific T cells. We therefore compared the effects of type I IFNs 
on adoptively co-transferred WT and Myd88-/- P14 cells isolated from LCMV infected 
recipients. Consistent with its role in promoting survival, we found that treatment with 
type I IFNs was able to rescue Myd88-/- P14 T cells from the spontaneous cell death that 
we had observed following ex vivo culture (Fig. 3.12D). Together, these results suggest 
that MyD88 is not required for IFN-induced signals in T cells, indicating that reduced 
responses to type I IFNs do not account for the reduced survival of Myd88-/- T cells 
following LCMV infection. 
 
3.13 Genome-wide microarray suggests differences in the expression of lipid 
phosphates and calcium signaling molecules in Myd88-/- P14 cells following LCMV 
infection 
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Since our studies had failed to identify a specific mechanism accounting for the reduced 
survival of Myd88-/- T cells, we decided to perform a full-genome microarray, theorizing 
that differentially expressed genes in Myd88-/- cells may provide insight into the role of 
MyD88 during LCMV infection. We therefore sorted adoptively cotransferred WT and 
Myd88-/- P14 cells from LCMV infected recipients, isolated RNA and performed an 
Agilent microarray to examine genome-wide differences in gene expression. We hoped to 
examine cells early in the response, reasoning that differences in the expression of 
relevant genes would precede differences in survival, however day 5 post infection was 
the earliest time point at which adoptively transferred P14 cells had expanded enough to 
allow us to sort sufficient cells for analysis.  
Overall, we noted that gene expression between WT and Myd88-/- P14 cells was 
fairly similar. We found a total of 116 genes that were overexpressed in Myd88-/- relative 
to WT P14 cells and 118 genes that were underexpressed with a fold change of 1.5 or 
greater. Functional annotation clustering analysis of these genes using the NIH DAVID 
database (Huang et al. 2009)(Dennis et al. 2003) identified 11 functionally related groups 
with an enrichment score of 1.0 or greater. Consistent with our earlier findings, we did 
not observe significant differences in genes related to TLR expression, Bcl-2 family 
members or type I IFN signaling. Amongst genes that were over-expressed in Myd88-/- 
cells we observed an enrichment of lipid phosphatases involved in phosphotidylinositol 
signaling (Fig 3.13A). Amongst genes that were underexpressed we observed enrichment 
of genes involved in calcium signaling (Fig 3.13B) and in amino acid metabolism (Fig 
3.13C). We also noted reduced expression of Myd88 and associated inflammatory genes 
(Fig 3.13D).  
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Overall, these microarray results support our earlier experiments, suggesting that 
MyD88 may be acting outside of its traditional role in TLR signaling during LCMV 
infection. Specifically, MyD88 may be contributing to calcium signaling pathways or 
amino acid metabolism, raising the possibility that defects in these pathways may account 
for the reduced survival of Myd88-/- T cells during LCMV infection. However, a number 
of caveats must be considered when interpreting these data. Firstly, while microarrays 
were performed in triplicate, they involved only a single sample of WT P14 RNA and 
Myd88-/- P14 RNA from 20 pooled infected recipients, making statistical significance 
difficult to assess. In addition, since cells were examined day 5 post infection, at which 
point differences in apoptosis and accumulation had already manifested, it is possible that 
these differences in gene expression represent consequences, rather than causes of the 
reduced survival of Myd88-/- cells. Furthermore, since there is considerable cellular 
heterogeneity in the LCMV response, it is possible that the Myd88-/- P14 cells that are 
present at this point in the response have already been selected for survival, eliminating 
the cells that are most susceptible to apoptosis from the analysis. Lastly, since this 
comparison did not include naïve WT and Myd88-/- P14 cells from uninfected animals, it 
is unclear which of these differentially expressed genes reflect basal differences in 
Myd88-/- T cells versus those that develop during LCMV infection. 
 
Summary 
Acute LCMV infection ordinarily elicits a robust expansion of virus-specific CD8 T 
cells, which play an important role in viral clearance. This expansion is critically 
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dependent on the presence of MyD88. The results in this chapter support a T cell-
extrinsic role for MyD88 in regulating T cell responses, as evidenced by the reduced 
expansion and a shift in the pattern of immunodominance during the response of WT 
CD8 T cells to LCMV infection in a Myd88-/- host (Section 3.3). This likely reflects 
reduced production of type I IFNs and other pro-inflammatory cytokines by Myd88-/- 
APCs(Jung et al. 2008), which have been shown to be important in regulating T cell 
expansion. Importantly, however, our results using polyclonal and TCR transgenic 
adoptive transfers and mixed bone marrow chimeras show that MyD88 also plays a 
critical, T cell-intrinsic role in supporting the accumulation of antigen specific CD8 T 
cells during the response to acute LCMV infection.  
Earlier studies have shown that MyD88-dependent signals delivered through TLR 
stimulation can directly regulate CD4 and CD8 T cell responses in vitro. While our 
results in this chapter extend these findings to show that MyD88-dependent signals in T 
cells are important during a physiological immune response to an infection in vivo, there 
are some notable differences between our findings and those suggested by earlier in vitro 
studies. Costimulation of naïve mouse T cells through TLR2 and TLR9 was shown to 
augment proliferation, survival and the production of effector cytokines and granzyme B. 
In contrast to these studies, our results indicate that MyD88-dependent signals are not 
required for proliferation or the acquisition of effector functions. Instead, the importance 
of MyD88 appears to be limited to a critical role in controlling the survival of effector T 
cells, thereby supporting their sustained expansion and accumulation.  
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Another notable finding in this chapter is that the dramatically reduced 
accumulation of Myd88-/- effector cells was not recapitulated by the absence of signals 
through TLR2, TLR9 or IL-1R family members. Thus, the upstream mediators of 
MyD88-dependent signals in T cells during LCMV infection may not be the TLR that 
have been suggested by in vitro studies. Furthermore, while TLR-induced survival 
pathways have been associated with the upregulated of Bcl-xL in vitro, we did not 
observe notable differences in Bcl-xL expression between WT and Myd88-/- T cells 
following LCMV infection. In addition, the increased apoptosis of Myd88-/- T cells 
following LCMV infection was not associated with an increased sensitivity to Fas 
mediated apoptosis or reduced responsiveness to type I IFNs. Differences in global gene 
expression instead indicate increased lipid phosphotase activity and reduced calcium 
signaling and amino acid metabolism in Myd88-/- T cells. 
 In conclusion, the findings in this chapter clearly demonstrate a previously 
unappreciated, T cell intrinsic role for MyD88 in regulating T cell expansion during and 
in vivo immune response to LCMV infection. While MyD88 expression in CD8 T cells 
during LCMV infection appears to be dispensable for initial activation, proliferation, and 
differentiation effector T cells, it is required for their survival and accumulation. The identity of 
the upstream stimuli and downstream signals that link MyD88 to T cell survival remain unclear 
and raise the possibility that MyD88 may function in an as yet undefined fashion outside of its 
traditional role in TLR signaling during LCMV infection. 
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Figure 3.1. Myd88-/- mice mount greatly reduced T cell responses to LCMV. WT and 
Myd88-/- B6 mice were infected with LCMV-Arm and splenocytes were purified 8 days after 
infection. (A) CD8 T cells were enumerated using antibodies against CD8a and CD44. Data 
represent mean +/- S.D. for at least 10 mice. (B) Splenocytes were restimulated ex vivo with the 
indicated LCMV-derived peptides and antigen-specific IFN production was assessed. (C-D) 
Gated CD8 T cells were analyzed with the indicated tetramers to determine the frequency (C) and 
number (D) of LCMV-specific CD8 T cells. Data represent mean +/- S.D of at least 10 mice. (E) 
PD-1 expression on tetramer-specific cells in WT and Myd88-/- mice was compared. 
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Figure 3.2. The phenotype of Myd88-/- mice following LCMV infection is not recapitulated 
by Tlr2-/-, Tlr9-/-, IL-1r-/- or IL-18r-/- mice. The indicated mice were infected with LCMV-
Arm and splenocytes were purified 8 days after infection. (A-B) Gated CD8 T cells were 
analyzed with the indicated tetramers to determine the frequency (A) and number (B) of LCMV-
specific CD8 T cells. Data represent mean +/- S.D of at least 5 mice. Splenocytes were 
restimulated ex vivo with the indicated peptides and CD8 T cell IFN production was assessed.
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Figure 3.3. WT CD8 T cells are able to expand and develop effector functions in response to 
LCMV in Myd88-/- hosts. (A) Experimental design. Splenocytes were examined 8 days after 
infection. (B) The number of donor cells per spleen was enumerated. Data represent mean +/- SD 
of at least 5 mice. (C-D) Splenocytes were restimulated with the indicated LCMV-derived 
peptides and the frequency (C) and number (D) of IFN-producing donor cells was determined. p 
< 0.05 for all values relative to corresponding WT controls. (E) The frequency of tetramer-
specific cells in the donor and host CD8 populations was compared. (F) PD-1 expression was 
examined on donor and host tetramer+ CD8 T cells. Data are representative of at least 5 mice.
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Figure 3.4. Myd88-/- CD8 T cells do not effectively expand in response to LCMV infection in 
WT hosts. (A) Experimental design. Splenocytes were examined 8 days after infection. (B) The 
number of adoptively transferred cells per spleen was enumerated. Data represent mean +/- SD of 
5 mice. (C and D) Splenocytes were restimulated with the indicated LCMV-derived peptides and 
the frequency (C) and number (D) of IFN-producing donor cells was determined. p < 0.01 for all 
values relative to corresponding WT controls. (E) The frequency of tetramer-specific cells in the 
donor and host CD8 T cell populations was compared. Data are representative of 5 mice per 
group. 
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Figure 3.5. Myd88-/- T cell defects following LCMV infection do not arise from 
development in a MyD88-deficient environment. (A) Experimental design. Splenocytes were 
examined 8 days after infection. (B-C) The ratio (B) and number (C) of CD45.1+ and CD45.2+ 
CD8 T cells was compared in infected and uninfected chimeras. Data show mean +/- SD of 5 
mice per group. (D) Tetramers were used to compare the frequency of LCMV-specific CD8 T 
cells within the CD45.1+ and CD45.2+ populations in the same mouse.(E) PD-1 expression on 
the tetramer+ CD8 T cells within the CD45.1+ and CD45.2+ in the same mouse was compared. 
Data are representative of 5 mice and differences in MFI were not significant. (F) Splenocytes 
were restimulated with the indicated peptides to examine LCMV-specific IFN production by 
WT and Myd88-/- CD8 T cells in the same mouse. Data are representative of 5 mice and p <  0.01 
for all stimulation conditions. 
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Figure 3.6. Myd88-/- P14 TCR transgenic T cells do not expand effectively in response to 
LCMV infection. (A) Experimental design. (B) The relative proportion of donor Myd88-/- P14 to 
WT P14 cells was compared on the basis of congenic Thy1.1 expression before and after LCMV 
infection. (C) The frequency of Myd88-/- P14 and WT P14 cells within the CD8 T cell population 
isolated from the indicated tissue compartment was determined using CD45.2 and Thy1.1 
congenic marker. Data show mean +/- SD of 5 recipient mice.
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Figure 3.7. Myd88-/- P14 TCR transgenic T cells develop a normal effector phenotype and 
effector functions following LCMV infection. Naïve Myd88-/- P14 and WT P14 cells were co-
transferred as in Fig. 3.6 and donor derived cells were examined in the spleens of recipients 7 
days after LCMV infection. (A-C) The expression of the indicated phenotypic markers was. (D) 
Granzyme B levels were compared on Myd88-/- P14 and WT P14 cells in the same mouse by 
intracellular staining directly ex vivo. Splenocytes were restimulated with gp33-41 peptide and 
IFN and TNF production by Myd88-/- P14 and WT P14 cells in the same mouse were 
compared by intracellular staining. All data are representative of 5 mice. No statistically 
significant differences in MFI were found.
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Figure 3.8. Myd88-/- and 
WT CD8 T cells 
proliferate comparably 
following LCMV infection. 
(A-B) WT and Myd88-/- 
mice were infected with 
LCMV and given a 24hr 
BrdU-pulse prior to 
sacrifice on day 8 post 
infection. BrdU 
incorporation by (A) overall 
CD8 T cells and (B) gated 
tetramer-specific cells was 
compared. Data show mean 
+/- SD of 4 mice. (C and D) 
CFSE-labeled congenic WT 
and Myd88-/- P14 cells 
were co-transferred into WT 
recipients which were infected with LCMV 18hrs later. The division profiles (C) and 
numbers (D) of WT and Myd88-/- P14 cells were compared in the spleens at the indicated 
time points. Data show mean +/- SD of 5 mice at each time point. (E) WT and Myd88-/- P14 
cells were co-transferred as in (C). Following a 12hr BrdU pulse, recipients were sacrificed at 
the indicated time points and BrdU incorporation by donor WT and Myd88-/- P14 cells was 
compared. Data show mean +/- SD of 4 mice at each time point. 
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Figure 3.9. Myd88-/- CD8 cells exhibit decreased viability following LCMV infection. Naïve 
WT and congenic Myd88-/- P14 cells were co-transferred into WT recipients as in Figure 3.8C. 
Splenocytes were isolated 4 days following infection and the viability of gated WT and Myd88-/- 
P14 cells was assessed by scatter properties, annexin V staining and the detection of total active 
caspases. Cells were examined either immediately ex vivo (left panels) or following a 20hr culture 
in the absence of exogenous peptides or cytokines (right panels). Data are representative of 5 
mice. p < 0.01 for the percentage of live Myd88-/- P14 cells relative to WT P14 cells as 
determined by scatter properties following 20hrs in culture. 
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Figure 3.10. Myd88-/- and WT P14 cells do not exhibit differences in the expression of Bcl2-
family members following LCMV infection. Naïve Myd88-/- and congenic WT P14 cells were 
cotransferred into WT recipients as in Figure 3.6. (A) Splenocytes were isolated at the indicated 
time point post infection and the expression of Bcl-xL, Bcl-2 and Bim was determined on gated 
Myd88-/- and WT P14 cells by intracellular staining. (C) Myd88-/- and WT P14 cells were 
FACS-purified and pooled from 20 recipients 4 days post LCMV infection. RNA was purified 
and the expression of the indicated Bcl2 family members was determined using an apoptosis PCR 
microarray. Data represent mean + SD of two independent experiments.
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Figure 3.11. Myd88-/- and WT T cell are comparably sensitive to Fas and TNF-induced 
apoptosis. Total T cells were MACS purified from the spleens and lymph nodes of naïve Myd88-
/- and CD45.1 congenic WT mice and co-cultured at a 1:1 ratio. Following primary activation by 
plate-bound CD3 and soluble CD28 in the presence of IL-2, live cells were isolated and re-
cultured under the indicated stimulation conditions. (A) After 24hrs, viability on gated Myd88-/- 
and WT CD4 and CD8 T cells was assessed by the detection of Annexin V and total active 
caspases. Data are representative of triplicate treatment groups in 2 independent experiments. 
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Figure 3.12. MyD88 expression is not required for T cell responses to Type I IFNs. (A) WT 
CD8 T cells were MACS purified from the spleens and LNs of naïve mice in the presence of 
plate-bound aCD3 and soluble CpG and recombinant mouse IFN as indicated. After 48hrs, Bcl-
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xL expression was determined by Western blotting. (B) CD8 T cells were MACS purified from 
the spleens and LNs of naïve WT and Myd88-/- mice, cultured for 24 hours in the presence or 
absence of plate-bound CD3 and then stimulated with recombinant mouse IFN for 30 minutes 
as indicated. The expression of phospho-STAT 1 and phospho-STAT 3 was determined by 
Western blotting. (C) CD8 T cells were MACS purified from the spleens and LNs of naïve 
congenic WT and Myd88-/- mice and co-cultured at a 1:1 ratio under the indicated conditions. 
Viability of gated WT and Myd88-/- cells was determined by scatter properties (top panels), or 
cells were fixed and granzyme B expression on gated WT and Myd88-/- CD8 T cells was 
compared following intracellular staining (lower panels). Data are representative of triplicate 
treatment groups in 2 independent experiments. (D) Naïve congenic WT and Myd88-/- P14 cells 
were transferred into WT recipients as in Figure 3.9. Splenocytes were isolated 4 days after 
LCMV infection and viability of gated WT and Myd88-/- P14 cells was determined based on 
scatter properties either directly ex vivo or following 20hrs of culture under the indicated 
conditions. Data are representative of triplicate treatment groups in 2 independent experiments.
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Figure 3.13. Myd88-/- P14 cells express higher levels of lipid phosphotase genes and lower 
levels of genes involved in calcium signaling and amino acid metabolism. Naïve Myd88-/- and 
congenic WT P14 cells were cotransferred into WT recipients as in Figure 3.6. Myd88-/- and WT 
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P14 cells were FACS-purified and pooled from 20 recipients 5 days post LCMV infection. RNA 
was purified and the gene expression was determined by a full-genome Agilent microarray. 
Differentially expressed genes with a fold change of 1.5 or greater were grouped into 
functionally-related clusters using the NIH DAVID software. The 4 clusters with the highest 
enrichment scores are shown. Data represent results from a single experiment in which pooled 
RNA samples were divided to perform triplicate microarrays. 
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CHAPTER 4: MyD88 is not required for the differentiation, 
maintenance and reactivation of memory T cells following LCMV 
infection 
 
Introduction 
The initial phase of rapid CD8 T cell expansion and differentiation into function effectors 
during acute LCMV infection is followed by a period of contraction during which 90-
95% of T cells undergo apoptosis. The remaining LCMV-specific T cells persist as a 
stable memory population. These memory T cells are maintained through slow 
homeostatic turnover that is independent of antigen, and instead relies on signals from the 
cytokines IL-7 and IL-15(Surh & Sprent 2008).  Following subsequent encounter with the 
same antigen, these memory T cells rapidly undergo expansion and differentiation into 
secondary effectors. Recent work suggests that the costimulation through TNFR family 
members plays an important role in maintaining the functional phenotype of memory T 
cells(Allam et al. 2009). Thus, the signals involved in the regulation of the memory T cell 
population are distinct from those involved in the regulation of naïve or effector cells.   
  Our results in Chapter 3 showed that MyD88 plays an intrinsic role in controlling 
the survival and expansion of T cells during the initial phase of antigen-driven 
proliferation following LCMV infection. As discussed earlier, it has been found that 
MyD88-dependent signaling through direct TLR costimulation can promote T cell 
differentiation into memory cells. Furthermore, memory T cells have been found to 
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express higher TLR levels and possess greater sensitivity to stimulation with TLR 
ligands. A recent study has shown that TLR2 ligands can act directly on memory CD8 T 
in the absence of specific antigen to promote proliferation and cytokine 
production(Cottalorda et al. 2009). These findings raise the possibility that MyD88-
dependent signals may play a role in regulating memory T cells generated in response to 
LCMV infection. We therefore examined whether the defective expansion of LCMV-
specific Myd88-/- T cells was also associated with additional defects in their contraction 
and differentiation into memory cells. 
 
4.1 Myd88-/- P14 cells generate a reduced frequency of memory cells following 
LCMV infection 
As we showed earlier, adoptively transferred Myd88-/- P14 cells expand considerably 
less than WT P14 cells resulting in significantly fewer cells in the spleens of recipient 
mice at the peak of the response, and also a similarly reduced number of memory cells 35 
days post infection (Figs. 3.6 and 4.1A). While their initial expansion was reduced, serial 
bleeds showed that Myd88-/- P14 cells contracted with comparable kinetics to WT P14 
cells (Fig 4.1B).  
The LCMV-specific effector T cell population contains considerable cellular 
heterogeneity at the peak of the response. In particular, a small subset of effector T cells 
expresses high levels of the IL-7R and low levels of killer cell lectin-like receptor G1 
(KLRG1).  In comparison to the majority of effector cells, which possess a 
KLRG1
high
IL7R
low
 phenotype, these KLRG1
low
IL7R
high
 cells have a considerably 
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greater potential of developing into long-lived memory cells. Thus, these 
KLRG1
low
IL7R
high
 cells have been termed memory precursor effector cells (MPECs), 
while the KLRG1
high
IL7R
low
 cells are primarily short lived effector cells (SLECs). We 
found that the population of Myd88-/- P14 cells contained a comparable proportion of 
SLECs and MPECs as WT P14 cells at the peak of the response, suggesting that the 
Myd88-/- and WT effector T cell pools contained similar memory potential (Fig 4.1C). 
Additionally, the majority of the Myd88-/- P14 cells that were present 35 days post 
infection exhibited the KLRG1
low
IL7R
high
 phenotype of memory cells.  
Thus, while these data show that Myd88-/- CD8 T cells generate fewer memory 
cells in response to acute LCMV infection, the phenotypic heterogeneity of the Myd88-/- 
effector population, its kinetics of contraction and the similar relative proportions of 
Myd88-/- and WT P14 cells at day 7 and day 35 post infection suggest that the reduced 
number of Myd88-/- memory cells may simply reflect their reduced initial expansion. 
 
4.2 T cells in Myd88T mice do not expand effectively in response to acute LCMV 
infection 
It is well established that the magnitude of the initial clonal burst significantly influences 
the size of the memory T cell compartment(S. Hou et al. 1994). Therefore, in order to more 
specifically examine whether MyD88 plays a role in the generation and maintenance of 
memory cells, independent of its role in regulating primary T cell expansion, we needed a 
system in which we could circumvent the defects associated with the absence of MyD88 
during initial LCMV infection. To achieve this, we made use of recently developed mice 
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in which the MyD88 gene has been floxed(B. Hou et al. 2008). While these mice had the 
potential to allow us to conditionally delete MyD88 in memory T cells, we first wanted to 
verify that deletion of MyD88 in naïve T cells using Myd88
flox/flox 
mice produced results 
consistent with our findings in Chapter 3 using germ-line Myd88-/- mice. We therefore 
crossed Myd88
flox/flox 
mice with mice expressing Cre recombinase under the CD4 
promoter(Lee et al. 2001). In the resulting mice, which we will subsequently term 
Myd88T  mice, MyD88 expression is selectively deleted in all  T cells on the basis of 
Cre expression starting at the CD4+CD8+ double-positive stage of thymocyte 
development (Fig 4.2A).  
We found greatly reduced CD8 T cell expansion in Myd88T mice in response to 
LCMV infection, resulting in dramatically reduced numbers of CD44high CD8 T cells in 
the spleens of infected Myd88T mice in comparison to Myd88flox/flox littermates that did 
not express Cre-recombinase (p < 0.01) (Fig. 4.2B). Strikingly, CD8 T cell numbers in 
Myd88T were reduced almost to the extent of complete Myd88-/- mice, supporting our 
earlier results in Chapter 3 and suggesting that the contribution of MyD88 to T cell 
expansion during LCMV infection is largely T cell intrinsic. Consistent with our earlier 
findings, we found that the reduced number of CD44
high
 CD8 T cells correlated with a 
reduced frequency of LCMV-specific effector cells, as identified by tetramer staining, in 
all tissues (p = 0.02) (Fig. 4.2C). Assessment of antigen-specific IFN production 
following ex vivo restimulation with LCMV-derived peptides also supported the reduced 
frequency of LCMV-specific effectors amongst both the CD8 and CD4 T cell populations  
(p < 0.01) (Fig. 4.2D). Interestingly, ex vivo restimulation indicated a greater reduction 
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in the frequency of cells responding to the np396-404 peptide than to the gp33-41 peptide 
in MyD88T mice, as we had observed in Myd88-/- mice. Overall, these findings confirm 
our earlier results, showing that MyD88 expression in T cells is critical for T cell 
expansion in response to LCMV infection, and establish that inducible deletion of 
MyD88 using Myd88
flox/flox 
mice represents an appropriate model for examining the role 
of MyD88 during LCMV infection.  
 
4.3 A system to conditionally delete MyD88 
To generate a system in which we could circumvent the defects associated with the 
absence of MyD88 during initial LCMV infection we crossed Myd88
flox/flox 
mice with 
transgenic mice expressing CreERT2 under transcriptional control of the ubiquitin 
promoter. To identify cells that underwent Cre-mediated deletion in these mice we 
further crossed them with R26RYFP Cre reporter mice in which the activity of Cre 
recombinase induces expression of YFP. To improve the efficiency of Cre-mediated 
deletion of MyD88 we used experimental mice in which only a single allele of MyD88 
needed to be deleted as the other was knocked out in the germline (Myd88
flox/- 
R26R
YFP
 
CreT2 mice, hereafter referred to as cKO). As controls we used mice in which one allele 
of MyD88 was floxed and the other was WT (Myd88
flox/+ 
R26R
YFP
 CreT2, hereafter 
referred to as cHet) (Fig. 4.3). 
Having generated these mice we wanted to confirm that tamoxifen treatment 
allowed the conditional deletion of MyD88 and that deleted cells could be identified on 
the basis of YFP expression. We therefore examined the effect of tamoxifen treatment on 
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the expression of MyD88 in splenocytes from cKO and cHet littermates. We found that 
tamoxifen treatment induced high expression of YFP in 25-50% of splenocytes in both 
cKO and cHet mice and that the proportion of YFP-expressing cells in the CD4 and CD8 
T cell compartments was comparable to the proportion in the overall splenocyte 
population (Fig 4.4A). In order to determine whether YFP served as an accurate reporter 
of MyD88 expression, we sorted the YFP+ and YFP- fractions from tamoxifen treated 
cKO and cHet mice or untreated controls and performed a western blot to assess MyD88 
protein levels. We found that the majority of YFP+ splenocytes in cKO mice had deleted 
MyD88 whereas there was minimal deletion in the YFP- compartment (Fig 4.4B). In 
contrast, MyD88 expression was comparable in YFP+ and YFP- splenocytes from cHet 
mice, suggesting that loss of a single Myd88 allele does not appreciably reduced MyD88 
protein expression. While this showed that tamoxifen treatment effectively induced 
MyD88 deletion in bulk YFP+ cKO splenocytes we also wanted to confirm that deletion 
occurred specifically in the T cell compartment. We therefore sorted YFP+ and YFP- 
CD4 and CD8 T cells from cKO mice and examined MyD88 expression by western blot. 
Consistent with the overall splenocyte population, we found that MyD88 was largely 
deleted in the YFP+ CD4 and CD8 T cells but was only minimally deleted in YFP- 
population (Fig 4.4C).  
To further confirm that that YFP+ cells in cKO mice reproduce the phenotype that 
we had observed in germline Myd88-/- T cells and Myd88T mice, we infected 
tamoxifen-treated cKO and cHet mice with LCMV. As expected, we observed 
significantly reduced expansion of the YFP+ CD8 T cells in cKO relative to cHet mice 
following LCMV infection (p = 0.02) (Fig 4.5A). In contrast, we did not observe a 
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significant difference in the expansion of the YFP- CD8 T cells in cKO relative to cHet 
mice (p = 0.27) (Fig 4.5B), supporting the limited deletion of MyD88 that we had 
observed in YFP- cKO T cells (Fig 4.4C). In further support of our finding that YFP- and 
YFP+ cells in cHet mice express comparable levels of MyD88 (Fig 3.3B) there was no 
significant difference between the expansion of YFP+ and YFP- CD8 T cells in cHet 
mice (p = 0.39), suggesting that heterozygous expression of MyD88 is sufficient to 
regulate T cell expansion in response to LCMV infection. Consistent with our earlier 
findings, the reduced CD8 T cell expansion in cKO mice correlated with a significantly 
reduced percentage of LCMV-specific effector cells in the YFP+ (p < 0.02) (Fig 4.5C), 
but not the YFP- CD8 T cell population (p > 0.74) (Fig 4.5D), as determined by antigen-
specific IFN production. Furthermore, this reduced percentage of YFP+ IFN-producing 
cells in cKO mice reflected a significantly reduced frequency of antigen-specific cells as 
determined by tetramer staining (p = 0.02) (Fig. 4.5E).  
Given that tamoxifen treatment of cKO presumably results in deletion of MyD88 
in multiple immune compartments, the fact that we observe significant differences in the 
expansion of YFP- and YFP+ T cell populations in cKO mice is consistent with our 
earlier findings supporting a T cell-intrinsic role for MyD88. In addition, the finding that 
there is no significant difference between the expansion of YFP- T cell population in 
cKO and cHet mice supports our earlier mixed bone marrow chimera experiments (Fig. 
3.5), which indicated that expression of MyD88 by half of the immune system is 
sufficient to support T cell responses against LCMV. Overall, these results demonstrate 
that tamoxifen treatment allows conditional deletion of MyD88 in cKO but not in cHet 
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mice and that YFP expression serves as an accurate reporter for MyD88 expression in 
cKO cells. 
 
4.4 MyD88 is not required for T cell contraction and memory differentiation 
following LCMV infection 
Having shown that the YFP+ T cells in cKO and cHet and effectively replicate the 
phenotype of germline Myd88-/- and Myd88+/- T cells following LCMV infection, we 
used matched cKO and cHet control mice to examine whether MyD88 plays a role in the 
contraction and differentiation of memory T cells independently of its role in initial 
expansion (Fig 4.6A). Following infection with LCMV-Arm we found no significant 
differences in the frequency of LCMV-specific CD8 T cells in the blood of cKO and 
cHet mice 8 days following infection (p = 0.66) (Fig 4.6B), confirming that Myd88 is 
haplo-sufficient for regulating initial T cell expansion We then treated mice with 
tamoxifen on day 10 post infection to delete MyD88 after the peak of the CD8 T cell 
response. Serial bleeds showed that tamoxifen treatment induced a comparable frequency 
of YFP+ cells in the blood both cKO and cHet mice and that these cells were maintained 
stably following infection (Fig 4.6C). This indicates that rejection of deleted cells on the 
basis of their acquired expression of YFP is not a concern in this system.  
We next examined the contraction and maintenance of LCMV-specific CD8 T 
cells following deletion of MyD88 by measuring their frequency in peripheral blood. 
Since we had found that MyD88 was only deleted effectively in the YFP+ population of 
cKO mice (Fig 4.4 and 4.5) we limited our analysis to YFP+ T cells. We found that the 
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populations of both gp33-specific (Fig 4.6D) and np396-specific (Fig. 4.6E) YFP+ CD8 
T cells contracted with similar kinetics and were maintained at a comparable frequency in 
the blood of cKO and cHet mice for up to 60 days post infection (p > 0.4 for all time 
points). 
 One of the attributes that distinguishes memory T cells from naïve T cells is their 
migration through peripheral tissues and bone marrow((Mackay et al. 1990)(Slifka et al. 
1997). Since in vitro studies have suggested that TLR stimulation may influence the 
expression of chemokines and integrins that regulate trafficking, we examined whether 
the loss of MyD88 influenced the trafficking of memory T cells. We found a comparable 
frequency of gp33-specific cells within the YFP+ lymphocyte population in the blood, 
spleen, lymph nodes, liver and bone marrow of cKO and cHet mice 60 days after LCMV 
infection (p > 0.72) (Fig 4.7A). This showed that the comparable frequency of LCMV-
specific memory cells detected in the blood of cKO and cHet mice reflected a comparable 
representation in other compartments, suggesting that MyD88 is not required for normal 
homing and circulation of memory cells.  
As discussed earlier, another attribute that distinguishes memory cells from naïve 
T cells is that they do not require TCR-derived signals for their maintenance and instead 
depend on the cytokines IL-7 and IL-15 for their homeostasis. It has recently been shown 
that stimulation through MyD88-dependent TLR pathways can promote memory T cell 
proliferation in response to IL-7(Cottalorda et al. 2009), raising the potential of decreased 
IL-7 responsiveness in MyD88-deficient memory T cells. However, consistent with their 
stable maintenance, we found that YFP+ LCMV-specific memory CD8 T cells in cKO 
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mice expressed comparable levels of CD127, CD122 and CD25 to those in cHet mice, 
suggesting normal recognition of these homeostatic cytokines (Fig 4.7B). In addition, we 
also found that YFP+ LCMV-specific memory cells in both cKO and cHet mice 
expressed a comparable distribution of CD62L, indicating that MyD88 is not required for 
differentiation into effector memory or central memory subsets (Fig 4.7B). We also noted 
that both cKO and cHet memory cells had downregulated PD-1 expression to the levels 
of naïve cells (Fig 4.7 B), further supporting a memory cell phenotype rather than a 
functionally exhausted phenotype. Overall, these findings indicate that, independent of its 
role in regulating primary expansion, MyD88 is dispensable for the differentiation, 
maintenance and migration of memory CD8 T cells following LCMV infection.    
   
4.5 MyD88 is not required for memory T cell effector functions 
As described earlier, another attribute of memory T cells is their ability to rapidly acquire 
effector functions in response to stimulation. It has recently been shown that the 
maintenance of memory T cells in a state of rapid responsiveness is dependent on the 
provision of adequate costimulatory signals through members of the tumor necrosis 
factor superfamily(Allam et al. 2009). Given that MyD88-dependent signals can serve as a 
T cell costimulatory pathway and TLR ligands can directly promote IFN secretion from 
memory T cells(Cottalorda et al. 2009), we examined whether the loss of MyD88 
influenced the ability of cKO memory cells to rapidly produce effector cytokines.  
60 days after LCMV infection, we found that a comparable frequency of YFP+ 
CD8 T cells in the splenocytes cKO and cHet mice produced IFNfollowing a brief 
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restimulation with LCMV-derived peptides (p > 0.4) (Fig 4.8A). Effector cytokine 
production was not limited to IFN since a comparable frequency of YFP+ CD8 T cells 
in cKO and cHet mice also produced TNF and IL-2 following restimulation (Fig. 4.8A). 
Furthermore, there was no significant difference in the overall distribution of memory 
cells that produced various combinations of these cytokines (p > 0.2) (Fig. 4.8B), 
suggesting that MyD88 is not required for the development of multifunctional memory 
cells We also found a comparable frequency of IFN and IL-2 producing cells in the 
YFP+ CD4 T cell compartment of cKO and cHet mice (p > 0.3) (Fig. 4.8A). These 
results indicate that MyD88-dependent signals are not required for the rapid production 
of effector cytokines by LCMV-specific memory T cells.   
 
4.6 MyD88 is not required for memory T cell responses to secondary infection 
Our results thus far indicate that T cell expression of MyD88 is required during initial 
expansion following LCMV infection, but is dispensable for the subsequent 
differentiation of functional memory cells. This raises the possibility that the MyD88-
dependent survival signals in effector T cells are triggered by ligands that are only 
present during active LCMV infection, and that the lack of a role for MyD88 in memory 
cells merely reflects that the relevant ligands are no longer present since virus has been 
cleared. Alternatively, it is possible that, once naive cells have differentiated into LCMV-
specific memory cells, signals through alternate pathways can compensate for the 
absence of MyD88-dependent signals. To distinguish between these possibilities, we next 
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examined whether MyD88 plays a role in controlling the survival and expansion of 
memory cells following secondary infection with LCMV.  
 Using cKO and cHet mice that had been infected with LCMV-Arm 60 days 
earlier and treated with tamoxifen following the primary response, we induced secondary 
infection with a high dose of LCMV-CL13. Reinfection induced a rapid expansion of 
CD8 T cells in both cKO and cHet mice. Notably, we observed a significantly lower 
frequency of YFP+CD44+ CD8 T cells in the blood of cKO than cHet mice 3 days 
following reinfection, however there was no longer a significant difference by day 6 (Fig 
4.9A). Surprisingly, we detected minimal expansion of the gp33-specific population in 
the blood of either cKO or cHet mice, but did find robust expansion of the np396-specific 
population (Fig. 4.9B), which has been reported to dominate secondary responses(Tebo et 
al. 2005). Consistent with the pattern in overall CD44+ cells, there was a significantly 
lower frequency of YFP+ np396-specific cells in the blood of cKO mice 3 days post 
reinfection, but both cKO and cHet mice contained a comparable frequency by 6 days 
post reinfection. This was mirrored by a comparable frequency of LCMV-specific CD8 T 
cells in the spleens of cKO and cHet mice 6 days post infection (p = 0.30) (Fig. 4.9C).  
Since we had observed increased apoptosis in Myd88-/- effector cells during 
primary expansion in response to LCMV, we examined the survival of LCMV-specific T 
cells following secondary expansion. Consistent with their comparable expansion, we 
found no notable differences in the apoptosis of YFP+ np396-specific cells in cKO and 
cHet mice either directly ex vivo, or following in vitro culture (Fig. 4.9D).  
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While these data suggested effective expansion and survival of MyD88-deficient 
memory T cells, it was possible that the secondary T cell response observed in cKO mice 
was due to the outgrowth of a population of YFP+ CD8 T cells that had failed to delete 
MyD88. We therefore sorted the YFP+ and YFP- fractions from the CD44+CD8 T cell 
populations in cKO and cHet mice and examined MyD88 expression. We found that the 
majority of YFP+ cells in cKO mice still lacked MyD88 expression, indicating that the 
memory T cell response in cKO mice did not merely reflect preferential expansion of 
MyD88-sufficient cells (Fig 4.9E). It should also be noted that some of the MyD88 
expression in the YFP+ cKO sample may represent contaminating YFP- cells since the 
sort purity of this sample was only 80%. 
We also considered whether MyD88 may potentially be involved in the 
differentiation of memory cells into functional secondary effectors. Ex vivo restimulation 
with LCMV-derived peptides indicated a comparable frequency of IFN producing cells 
within the YFP+ CD8 T cell compartments of cKO and cHet mice (4.10A), as well as a 
similar frequency and distribution of cells that produced combinations of IFN, TNF 
and IL-2 (p > 0.1) (4.10B). Interestingly, in contrast to our results using gp33 tetramers, 
we found that secondary LCMV infection induced a considerable expansion in the 
population of cells that produced IFN in response to restimulation gp33-41 in both cKO 
and cHet mice. This could indicate preferential expansion of cells recognizing the epitope 
in the context of H2-K
b
 during the secondary immune response to LCMV. Overall, these 
data indicate that, while MyD88-expression may contribute slightly to the kinetics of 
early memory T cell expansion following secondary LCMV infection, the MyD88-
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dependent signals induced by LCMV infection are not critical for memory T cells to 
achieve maximal expansion or differentiation at the peak of the secondary response. 
  
Summary 
It is well established that memory T cells are functionally and phenotypically distinct 
from naïve and effector T cells. For example, memory T cells rely on the cytokines IL-7 
and IL-15, rather than TCR-induced signals for their homeostasis and concordantly 
express higher levels of the IL-7R and IL-15R than naïve T cells. Studies have also found 
that memory T cells constitutively expresses higher levels of TLRs and are more 
responsive to TLR ligands than naïve T cells, thus raising the possibility that MyD88-
dependent pathways may play a more important role in regulating memory T cell 
responses. However, our results in this chapter indicate that, following the primary 
response to acute LCMV infection, LCMV-specific T cells do not require MyD88-
dependent signals to support their differentiation into memory cells or their subsequent 
maintenance. Furthermore, in contrast to the critical requirement for MyD88 in 
supporting naïve T cell expansion in response to primary LCMV infection, memory T 
cells expand and differentiate effectively following secondary encounter with LCMV in 
the absence of MyD88. Thus, differential requirements for MyD88-dependent signaling 
appear to represent another attribute that functionally distinguishes memory T cells from 
naïve T cells. 
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Figure 4.1. Myd88-/- P14 cells generate fewer memory cells following LCMV 
infection. Myd88-/- or WT P14 cells were transferred into individual WT recipients, which were 
infected 18hrs later. (A) On day 7 and day 35 post infection the numbers of WT and Myd88-/- 
P14 cells per spleen were enumerated. Data represent mean + S.D of 9 mice and p < 0.01 for both 
time points. (B) LCMV-infected recipients were longitudinally bled and the percentage of WT 
and Myd88-/- P14 cells was determined relative to total CD8 T cells. Data represent mean +/- SD 
of at least 9 mice and p < 0.01 for all time points. (E) Expression of KLRG-1 and IL-7R by WT 
and Myd88-/- P14 cells in day 7 and day 35 infected spleens. Data are representative of 5 mice 
and differences were not statistically significant. 
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Figure 4.2. Myd88T mice mount greatly reduced T cell responses to LCMV infection. (A) T 
and B cells were FACS purified from the spleen of a Myd88T mouse and MyD88 expression 
was examined by Western blot. (B-D) Myd88flox/flox, Myd88T and Myd88-/- mice were 
examined 8 days after LCMV infection. (B) The number of splenic CD8 T cells was determined. 
Data represent mean + SD of 4 mice per group. (C) The frequency of tetramer-specific cells 
amongst gated CD8 T cells from the indicated tissues was measured. (D) Splenocytes were 
restimulated with the indicated peptides and antigen-specific IFN production was assessed. 
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Figure 4.3. Schematic of the predicted outcome of tamoxifen treatment in cKO and 
cHet mice 
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Figure 4.4. Tamoxifen treatment allows deletion of MyD88 correlated with YFP expression 
in cKO mice. (A) cHet mice cKO mice were treated with tamoxifen or left untreated and YFP 
expression in the indicated splenocyte populations was determined 5 days later. (B) YFP+ and 
YFP- splenocytes were FACS-purified from treated or untreated cHet and cKO mice. MyD88 
expression was determined by Western blot. (C) YFP+ and YFP- CD4 and CD8 T cells were 
FACS-purified from treated or untreated cKO mice and MyD88 expression was determined by 
Western blot. 
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Figure 4.5. YFP+ T cells in cKO mice exhibit reduced expansion in response to LCMV 
infection. cKO and cHet mice were treated with tamoxifen and infected with LCMV-Arm 5 days 
later. Splenocytes were examined 8 days after infection. (A-B) The frequency of CD8 T cells in 
the YFP+ (A) and YFP- (B) splenocyte populations was determined. (C-D) Splenocytes were 
restimulated with the indicated peptides and the frequency of IFN-producing YFP+ (C) and 
YFP- (D) CD8 T cells was determined by intracellular staining. (E) The frequency of LCMV-
specific YFP+ CD8 T cells was determined using tetramers. All graphs represent mean + SD of at 
least 4 mice.
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Figure 4.6. MyD88 is not required for the development and maintenance of memory T cells 
following LCMV infection. (A) Experimental design. (B) The frequency of tetramer-specific 
CD8 T cells in the blood of cKO and cHet mice was determined 8 days after LCMV infection. 
Data represent mean + SD of at least 6 mice. (C) The frequency of YFP+ cells was measured in 
blood lymphocytes of cKO and cHet mice by serial bleeds. Data represent mean +/- SD of at least 
6 mice. (D-E) The frequency of gp33-specific (D) and np396-specific (E) cells within YFP+ 
blood lymphocytes of cKO and cHet mice was determined by tetramer staining. Data represent 
mean +/- SD of at least 6 mice. 
93 
 
 
 
Figure 4.7. MyD88 is not required for normal T cell tissue homing or the acquisition of a 
memory phenotype following LCMV infection. cKO and cHet mice were infected with 
LCMV-Arm and treated as in Figure 4.6 (A) The frequency of gp33-specific cells within the 
YFP+ CD8 T cells from the indicated tissues of cKO and cHet mice was assessed by tetramer 
staining 60 days after infection. (B) The expression of the indicated phenotypic markers was 
determined on gated gp33-specific YFP+ cells from the spleens of cKO and cHet mice 60 days 
after infection. 
94 
 
 
Figure 4.8. MyD88 is not required for the rapid production of effector cytokines by memory 
T cells. (A) Splenocytes from cKO and cHet mice 60 days following LCMV infection were 
restimulated with the indicated LCMV-derived peptides and IFN, TNF and IL-2 production by 
YFP+ CD8 T cells was assessed by intracellular staining. (B) The frequency of YFP+ CD8 T 
cells producing the indicated combinations of cytokines in response to stimulation with pooled 
LCMV peptide was determined. Data represent mean + SD of 3 mice. 
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Figure 4.9. MyD88 is not critical for memory T cell expansion in response to secondary 
LCMV infection. cKO and cHet mice were infected with LCMV-Arm and treated as in Figure 
4.6, and were reinfected with LCMV-CL13 60 days after primary infection. (A-B) The frequency 
of CD44+ (A) and np396-specific (B) YFP+ CD8 T cells in the blood at the indicated time points 
was determined by tetramer staining. Data show mean +/- SD of 3 mice. (C) The frequency of 
tetramer specific YFP+ CD8 T cells in the spleens of cKO and cHet mice was assessed 6 days 
post reinfection. (D) YFP+ and YFP- CD44+CD8 T cells were sorted from the spleens of 
reinfected cKO and cHet mice and MyD88 expression was measured by Western blot. (D) The 
viability of gated np396-specific YFP+ CD8 T cells from cKO and cHet mice was assessed by 
Annexin V staining direct either ex vivo or after the indicated 20 hours of in vitro culture as 
indicated. Data are representative of 3 mice per group. 
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Figure 4.10. MyD88 is not required for the differentiation of memory T cells into secondary 
effectors. LCMV immune cKO and cHet mice were reinfected with LCMV Cl-13 as in Figure 
4.9. (A) 6 days after reinfection, splenocytes were restimulated with the indicated LCMV-derived 
peptides and IFN, TNF and IL-2 production by YFP+ CD8 T cells was assessed by 
intracellular staining. (B) The frequency of YFP+ CD8 T cells producing the indicated 
combinations of cytokines in response to stimulation with pooled LCMV peptide was determined. 
Data represent mean +SD of 3 mice per group. 
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CHAPTER 5: Discussion and Speculation 
Defining the role of MyD88 in T cells: contrasting the findings of in vitro and in vivo 
studies  
A growing number of studies have recently shown that TLR ligands can act directly on 
mouse and human T cells to promote their proliferation, survival and differentiation in 
vitro, challenging the prevailing view that suggested that the importance of TLRs was 
restricted to cells of the innate immune system. These findings raised the potential that 
the defective T cell responses against numerous pathogens that had been observed in 
MyD88 mice may reflect a direct role for MyD88-dependent signaling in T cells. 
However, the relative contributions of T cell extrinsic and intrinsic MyD88-dependent 
signals and, thus, the overall physiological relevance of MyD88-expression in T cells, 
during a natural in vivo immune response remained unclear.  
The findings presented in this dissertation being to address these issues by using 
LCMV infection as model viral pathogen to examine the role of MyD88 during in vivo T 
cell responses. We confirm that MyD88 plays an important T cell-extrinsic role in regulating T 
cell responses, as evidenced by reduced expansion and a shift in immunodominance during the 
response of WT CD8 T cells to LCMV infection in a Myd88-/- host (Chapter 3.3). This supports 
the reduced production of type I IFNs and other pro-inflammatory cytokines by Myd88-/- 
APCs(Zhou et al. 2005)(Jung et al. 2008), which, in turn, have been shown to be important in 
regulating T cell expansion(Kolumam et al. 2005)(Aichele et al. 2006). However, our findings 
importantly show that MyD88 also plays a critical, T cell-intrinsic role in supporting the survival 
and accumulation of antigen specific CD8 T cells during the response to acute LCMV infection. 
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During the course of this dissertation work, a number of other studies have 
expanded upon earlier in vitro work to examine the potential role of TLR and MyD88-
dependent signaling in T cells during in vivo immune responses. As discussed earlier, 
Myd88-/- mice display significantly greater mortality following infection by the 
protozoan pathogen, Toxoplasma gondii(Scanga et al. 2002). This increased susceptibility 
is associated with reduced Th1 effector responses, which have been attributed to 
defective innate immune activation and reduced levels of IL-12 production in these mice. 
In a recent study, our lab found that mixed bone marrow chimeras in which MyD88-
deficiency was largely restricted to the T cell compartment generated reduced numbers of 
IFN-producing effector T cells following T. gondii infection and were highly susceptible 
to toxoplasmic encephalitis, succumbing to infection with similar kinetics to full Myd88-
/- mice(LaRosa et al. 2008). These findings indicate that MyD88 expression in T cells is 
required for prolonged resistance to T. gondii in the setting of an intact innate immune 
response but did not establish a mechanism by which MyD88 contributes to T cell 
responses in this model. 
MyD88 expression in T cells was also found to play a role in CD4 T cell-
mediated colitis. When CD4+CD45RB
high
 T cells are transferred into RAG1/2-deficient 
animals, the recipients rapidly develop wasting disease associated with clinical signs of 
colitis(Powrie et al. 1993)(Morrissey et al. 1993). This experimental colitis depends on the 
presence of commensal intestinal microflora and TLRs from these microorganisms are 
thought to activate innate immune cells in the gut and thereby indirectly support 
colitogenic T cell responses(Cong et al. 1998)(Sartor 2001). However, it has recently been 
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reported that purified MyD88-/- CD4+CD45RB
high
 T cells transferred into RAG-deficient 
recipients do not induce as severe colitis as WT T cells(Tomita et al. 2008)(Fukata et al. 
2008). Using competitive transfer systems, Myd88-/- colitogenic CD4 T cells were shown 
expand less effectively than WT cells and this correlated with reduced production of 
effector cytokines. In particular, MyD88-/- CD4 T cells isolated from the lamina propria 
produced significantly less IL-17. Furthermore, it was shown that Myd88-/- CD4 T cells 
did not effectively differentiate into IL-17-producing cells in vitro, suggesting that 
MyD88 may play a role in Th17 polarization(Fukata et al. 2008). Relevant to this, Myd88-
/- mice are highly resistant to the induction of experimental autoimmune encephalitis 
(EAE), which is an IL-17 mediated autoimmune disease(Marta et al. 2008). While reduced 
numbers of Myd88-/- Th17 cells in this model have been attributed to decreased 
production of IL-6 and IL-23 by Myd88-/- dendritic cells, it is interesting to consider 
whether they also reflect a T cell-intrinsic role for MyD88 in supporting Th17 responses. 
These studies using T. gondii and colitis models demonstrated that MyD88-
dependent signals in T cells are a physiologically relevant component of T cell responses 
in vivo. However, since they were only able to examine overall polyclonal T cell 
responses, these studies were limited in their ability to directly compare antigen-specific 
populations of WT and MyD88-/- effector T cells. Thus, while reduced levels of CFSE 
dilution and BrdU uptake were identified in MyD88-/- colitogenic CD4 T cell 
populations, it remained unclear whether this represented reduced proliferation of 
antigen-specific T cell clones or increased cell death resulting in a smaller proportion of 
dividing colitogenic cells. Similarly, it was unclear whether impaired cytokine production 
by MyD88-/- T cell populations in these models represented impaired effector 
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differentiation, reduced cytokine secretion by antigen-specific responders, or a relatively 
smaller proportion of cytokine-producing effector cells.    
The findings presented in this dissertation support and expand upon these studies 
to further define the role of MyD88 in T cells during viral infection. The use of LCMV as 
an infection model allowed us to employ epitope-specific cytokine production, MHC 
Class I tetramers and P14 TCR-transgenic mice to directly compare the responses of WT 
and MyD88-deficient antigen-specific T cells. Our results in Chapter 3, using adoptive 
cells transfers and bone marrow chimeras, clearly demonstrate that MyD88 plays a T 
cell-intrinsic role in supporting T cell expansion, but not effector differentiation, in 
response to LCMV infection. While this reduced expansion is associated with decreased 
BrdU incorporation in the overall Myd88-/- CD8 T cell population, examination of 
LCMV-specific effector cells allow us to attribute the reduced expansion to impaired 
survival rather than impaired proliferation. Interestingly, examination of the polyclonal T 
cell response indicated the absence of MyD88 resulted in a more severe reduction in 
np396-specific than gp33-specific T cells. This may relate to the fact that T cells 
responding to the np396 epitope express higher levels of PD-1 and have been found to be 
in a more apoptotic state than those responding to gp33 epitope(X. Z. Wang et al. 2004), and 
may thus be more dependent on MyD88-dependent signals to rescue them from 
apoptosis. 
Thus, while in vitro studies have suggested that MyD88-depndent TLR signals 
can potentially regulate CD8 T cell proliferation, survival and effector 
differentiation(Cottalorda et al. 2006), our results in Chapter 3 indicate that naïve CD8 T 
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cells can be activated and induced to proliferate and differentiate into functional and phenotypic 
effector cells during the early stages of the response to LCMV in the absence of MyD88. Instead 
the importance of MyD88 is limited to a critical role in supporting their subsequent survival and 
sustained accumulation, thereby controlling the ultimate size of the T cell effector 
population at the peak of the response (Fig. 5.1). Thus, MyD88-dependent signals appear 
to act in an analogous fashion to inflammatory cytokines, which serve as a third signal, in 
addition to TCR and costimulatory receptor engagement, in promoting optimal T cell 
expansion(Curtsinger et al. 2005). Our results are supported by recent studies that also 
indicate a similar role MyD88 in antigen-specific T cells during responses to LCMV and 
vaccinia virus infection(Bartholdy et al. 2009)(Quigley et al. 2009)(Zhao et al. 2009). This 
suggests that the defects associated with Myd88-/- T cells in the T. gondii and colitis 
models may also primarily be explained by reduced effector cell survival rather than 
impairments in proliferation or effector cell differentiation, though it is difficult to 
extrapolate findings between these experimental systems since the precise nature of the 
MyD88-mediated signals may vary. 
In vitro studies have also suggested that MyD88-dependent TLR signals may 
contribute to the differentiation, homeostasis and reactivation of memory T cells(Mercier 
et al. 2009)(Cottalorda et al. 2009). We find that MyD88 expression in T cells is important 
in regulating the size of the resulting memory population following LCMV infection and 
a similar finding has been reported following vaccinia virus infection(Quigley et al. 2009). 
However, this likely reflects an indirect result of the importance of MyD88 in supporting 
initial T cell expansion, since initial antigen encounter and the number of effector cells 
generated during the primary response are known to regulate the differentiation and 
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ultimate size of the memory population(Hou et al. 1994)(Shaulov & Murali-Krishna 2008). 
Indeed, our results in Chapter 4 indicate that, independent of its role in the initial phase of 
T cell expansion, MyD88-expression is not required for the subsequent differentiation 
and maintenance of functional memory T cells. Furthermore, memory T cells appear to 
be less dependent on MyD88-dependent signals than naïve T cells for their expansion in 
response to secondary LCMV infection. Similarly, memory T cells induced in Myd88-/- 
mice by vaccination with gp33-expressing adenovirus were also shown to expand 
effectively in response to LCMV infection(Bartholdy et al. 2009). Thus, while in vitro 
studies suggest a role for MyD88-dependent signals in regulating memory T cell 
homeostasis and responses, it appears this these signals are not critical during in vivo 
responses to LCMV infection. 
 
A consideration of the potential mechanisms for MyD88-mediated T cell survival 
during infection 
Perhaps the most notable difference between our results and those suggested by in 
vitro studies is that the role of MyD88 during LCMV infection does not appear to be 
attributable to a specific TLR pathway. While TLR2 and TLR9 are the only MyD88-
dependent TLR pathways that have been found to stimulate mouse CD8 T cells in vitro, 
neither Tlr2-/- nor Tlr9-/- mice recapitulated the impaired T cell expansion observed in 
Myd88-/- mice following LCMV infection. Indeed, Tlr2-/- mice exhibited significantly 
increased numbers of LCMV-specific cells in their spleens at the peak of infection. This 
surprising finding could potentially be related to the reduced frequency of Tregs reported 
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in these mice(Netea et al. 2004) or to reduced recruitment of T cells into other tissues due 
to impaired chemokine production(Zhou et al. 2008). It has been shown that mice deficient 
in TLR3, TLR4, and TLR8 mount normal CD8 T cell responses to LCMV, and while 
LCMV-specific CTL numbers are slightly reduced in mice lacking both TLR7 and TLR9, 
they do not recapitulate the phenotype of Myd88-/- mice (Jung et al. 2008).  
MyD88 is also involved in signaling downstream of the IL-1R and IL-18R, and 
these cytokines have been shown to play a role in promoting CD8 T cell survival(Wen Li 
et al. 2007). However, we found no reduction in LCMV-specific CD8 T cells in the 
spleens of IL1r1-/- mice and somewhat reduced numbers in IL18r1-/- mice, which still 
greatly exceeded those found in Myd88-/- mice, suggesting that these pathways also do 
not account for the importance of MyD88 during LCMV infection. IL-33, which signals 
through ST2, has also recently been described as another IL-1R family cytokine. IL-33 
signaling has been implicated in the polarization of TH2 CD4 T cells(Schmitz et al. 2005), 
but has not been described to play a role in CD8 T cells. While this suggests that IL-33 is 
unlikely to account for the impaired responses of Myd88-/- CD8 T cells, its potential role 
cannot yet be ruled out.  
Thus, while MyD88 clearly plays an important role in T cells during responses to 
LCMV infection, the specific upstream initiators of MyD88-mediated signaling remain 
unclear. Similarly, the T cell impairments associated with MyD88-deficiency during T. 
gondii infection cannot be attributed to a role for individual TLRs or IL-1 and 
IL18(Scanga et al. 2002)(Debierre-Grockiego et al. 2007)(Hitziger et al. 2005)(Yarovinsky et al. 
2005)(LaRosa et al. 2008). In addition, while the role of MyD88 in vaccinia virus specific T 
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cells has been attributed to TLR2 signaling in one study(Quigley et al. 2009), another was 
unable to find such an association(Zhao et al. 2009). This suggests that an inability to 
define a role for specific TLR/cytokine pathways may be a consistent feature when 
considering the importance of MyD88 in T cells during in vivo immune responses. One 
possible explanation for this is that there is considerable redundancy and cooperation 
between different MyD88-dependent pathways in vivo, as has been noted in certain 
infections (Sørensen et al. 2008). Another, non-mutually exclusive, possibility is that the 
importance of MyD88 in CD8 T cells during infection is linked to novel upstream 
receptors or a function outside of its traditional role in TLR signaling.  
In support of this latter possibility, while TLR-induced survival of T cells is 
associated with clear upregulation of Bcl-xL expression in vitro(Cottalorda et al. 2006), we 
did not detect significant differences in the levels of this pro-survival factor between WT 
and Myd88-/- CD8 T cells following LCMV infection. Instead the results of a full 
genome microarray suggested that the reduced survival of Myd88-/- cells may be related 
to differences in the expression of genes related to inositol phosphate metabolism, 
calcium signaling and amino acid metabolism. Though the significance of these findings 
is somewhat unclear, it is interesting to note that a potential connection between MyD88-
dependent signaling pathways and regulation of cellular metabolism is suggested by a 
recent study that found that TRAF6-deficient CD8 T cells exhibit alteration of genes 
regulating fatty acid metabolism following Listeria monocytogenes infection(Pearce et al. 
2009). 
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In considering other potential roles for MyD88 outside of TLR signaling we noted 
that MyD88 has been found to associate with the Fas-related signaling molecule, FADD 
in fibroblasts and macrophages. As a result of homotypic death-domain interactions, 
expression of FADD can inhibit signaling through TLRs by sequestering MyD88 away 
from TLR signaling pathways(Zhande et al. 2007). This raised the reciprocal possibility 
that loss of MyD88 may allow excess FADD to be recruited to the Fas signaling pathway, 
thereby rendering Myd88-/- T cell hyper-responsive to Fas induced apoptosis. However, 
we did not find that Myd88-/- T cells had increased sensitivity of Fas or TNF induced 
AICD in vitro, suggesting that these pathways do not account for the reduced survival of 
Myd88-/- T cells following LCMV infection. However, an interaction of MyD88 with 
other death-domain containing proteins remains a possibility.  
It is also interesting to note the striking similarity in the apparent roles of Type I 
IFN and MyD88-dependent signals in T cells during LCMV infection. Like Myd88-/- T 
cells, IFN-IR-/- T cells proliferate and differentiate but exhibit reduced survival, resulting 
in dramatically reduced expansion following LCMV infection(Aichele et al. 
2006)(Kolumam et al. 2005). While this similarity in phenotype may be coincidental, it is 
tempting to speculate that it may reflect an intersection between the IFN-IR and MyD88 
signaling pathways. As discussed earlier, MyD88 is known to play an important role in 
promoting the production of Type I IFNs through the induction of IRF-dependent 
signaling pathways(Taro Kawai et al. 2004). However, a potential role for MyD88 
downstream of Type I IFN induced signaling pathways is less clear. TLR signaling has 
been shown to promote STAT1 phosphorylation in macrophages, raising the potential 
that MyD88 may be involved in STAT-dependent cytokine responses(Rhee et al. 2003). 
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However, given that TLR signaling has been shown induce the production of IFN in 
APCs, this finding may reflect a secondary outcome of increased IFN production. In 
support of this, we did not observe defects in STAT phosphorylation or general responses 
to Type I IFNs in Myd88-/- CD8 T cells, though this does not rule out a more subtle role 
for Type I IFNs in promoting MyD88-dependent signals or vice versa.  
Notably, similarly to IFN-IR-/- CD8 T cells, IFNR1-/- CD8 T cells have also 
been shown to exhibit reduced expansion in response to LCMV infection(Whitmire et al. 
2005), though the mechanisms by which IFN directly promotes CD8 T cell abundance 
remain unclear. Interestingly, MyD88 has been shown to physically interact with the 
IFNR1 and thereby stabilize IFN-induced mRNA transcripts in macrophages(Sun & Ding 
2006). This raises the intriguing possibility that MyD88 may function similarly in CD8 T 
cells, suggesting that the reduced survival of Myd88-/- CD8 T cells following LCMV 
infection reflects impaired expression of IFN-induced survival genes. Furthermore, a 
similar association between MyD88 and the IFN-IR remains an unexplored possibility. 
 In considering the role of Type I IFNs in regulating T cell responses, it is notable 
that T cells appear to be particularly dependent on IFN-IR-mediated signals for their 
clonal expansion in the setting of LCMV infection. In contrast, T cell expansion in 
response to vaccinia, VSV and Listeria monocytogenes infection is only mildly impaired 
in the absence of IFN-IR signaling(Thompson et al. 2006). Correspondingly, while 
MyD88-dependent signals are critical for T cell survival in the setting of LCMV and 
vaccinia infection(Quigley et al. 2009)(Zhao et al. 2009), it is interesting to note that there is 
no significant reduction in the expansion of Myd88-/- T in response to VSV(Bartholdy et 
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al. 2009) and only moderately impaired expansion in response to adenovirus(Bartholdy et 
al. 2009) and Listeria infection (S. M. Kaech, unpublished observations). Furthermore, 
while we have found that MyD88-expression in T cell is required for resistance to T. 
gondii(LaRosa et al. 2008), it is notable that loss of MyD88 results in a far smaller 
reduction in effector CD8 T cell frequency during T. gondii infection than LCMV 
infection.  
Thus, it appears that MyD88-dependent signals are not universally required for 
promoting T cell expansion and their importance is instead linked to certain infections. 
This could indicate that the upstream ligands that trigger the relevant MyD88-dependent 
pathways in T cells are only encoded by, or induced in the setting of, certain pathogens. 
Alternatively, and non-exclusively, it is possible that other characteristics of the infection 
dictate the relative importance of MyD88-dependent signals in contributing to overall T 
cell survival. Due to its non-cytopathic nature, LCMV provides a very large antigenic 
load, which is an important contribution to the dramatic T cell expansion induced by this 
virus (Thompson et al. 2006). In addition, studies using different strains of LCMV indicate 
that the Myd88-/- T cell response is more significantly impaired following infection high-
dose with the invasive LCMV-Traub strain than the acute LCMV-Arm strain(Bartholdy et 
al. 2009). This could indicate that an environment of prolonged antigenic load is an 
important factor in determining the importance of MyD88-dependent survival signals. 
Consequently, the more severe impairment in the np396-specific responses may be 
related to higher antigen loads of this immunodominant epitope(van der Most et al. 2003). 
This could also suggest that the relatively minor role for MyD88-expression in memory T 
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cell expansion following secondary LCMV infection is related to the relatively rapid 
clearance of virus. To further explore this possibility we are interested in examining the 
role of MyD88-dependent signals in regulating T cell survival and maintenance in the 
setting of persistent antigen exposure induced during chronic LCMV infection(Wherry et 
al. 2003). 
While this potential avenue of investigation would serve to further define the role 
of MyD88 in T cells during infection, additional insight would be gained by identifying 
the critical upstream and downstream mediators that are responsible for conferring the 
ability of MyD88 to promote T cell survival during LCMV infection. As discussed 
earlier, MyD88 is known to engage upstream receptors through homotypic TIR domain 
interactions and subsequently recruit IRAK4 through homotypic death domain 
interactions ultimately leading to NFB activation(Wesche et al. 1997)(Martin & Wesche 
2002). However, additional studies have found that MyD88 is also able to activate the Akt 
pathway through a direct interaction of phosphatidylinositol 3-kinase (PI-3-K) with a 
tyrosine motif in the MyD88 TIR domain(Li et al. 2003)(Rhee et al. 2006)(Gelman et al. 
2006). At present it is unclear which, if any, of these pathways is responsible for the 
MyD88-induced survival effect during LCMV infection.  
The fact that TLR stimulation can promote Akt phosphorylation in vitro, and that 
Akt signaling is required for T cell responses to vaccinia has led others to conclude that 
Akt activation represents the critical MyD88-dependent pathway during infection, though 
this has not been directly demonstrated(Quigley et al. 2009). Indeed, we have found that the 
Akt pathway primarily contributes to TLR-induced T cell proliferation rather than 
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survival(Gelman et al. 2006), which is inconsistent with our finding that Myd88-/- T cells 
have a specific defect in survival rather than proliferation. Furthermore, the fact that mice 
lacking IRAK4, the signaling kinase downstream of MyD88, also exhibit reduced T cell 
expansion in response to LCMV(Lye et al. 2008) suggests that this may represent the 
relevant pathway during LCMV infection. However, this hypothesis is complicated by 
the finding that T cells lacking TRAF6, the signaling molecule downstream of IRAK4, 
do not exhibit impaired expansion but rather impaired memory differentiation following 
Listeria infection(Pearce et al. 2009), contrasting with the phenotype of Myd88-/- T cells. 
In addition, since Bcl-xL expression is upregulated as a result of MyD88-induced NF-B 
activation, the fact that we did not observe differences in the expression of Bcl-2 family 
members further questions the role of this pathway in regulating T cell survival during 
LCMV infection.  
In considering how to clarify some of these issues, it is useful to note that studies 
have begun to identify the molecular motifs associated with MyD88 TIR and Death 
domain interactions(Ohnishi et al. 2009)(Chunsheng Li et al. 2005)(Loiarro et al. 2009)(Gelman 
et al. 2006). It is therefore potentially feasible to generate mutated forms of MyD88 that 
are unable to initiate specific signaling pathways. By transfecting Myd88-/- deficient cells 
with mutant forms of MyD88, the relative importance of various domains of MyD88 in 
promoting T cell survival during LCMV infection could be selectively assessed. This 
approach could help to clarify the critical binding partners of MyD88 and elucidate the 
relevant signaling pathways, thereby establishing a more comprehensive mechanism for 
the physiological role of MyD88 in T cells. 
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Conclusions 
     MyD88-dependent signaling through TLRs has long been recognized to play 
an important, indirect role in supporting T cell responses through myriad effects on innate 
immune cells, including up-regulating antigen presentation, co-stimulatory molecule 
expression and inflammatory cytokine production. In addition to these importance effects 
in cells of the innate immune system, it is now clear that MyD88-dependent TLR ligands 
can also directly on T cells. Several in vitro studies have shown that TLRs can potentially 
serve as co-stimulatory receptors on T cells, and that their engagement supports TCR-
mediated signals, promoting effector responses including enhanced cytokine production, 
proliferation and survival. This dissertation builds on this work to clearly demonstrate 
that MyD88-dependent signals in T cells play a critical role in supporting in vivo T cell-
responses against a viral pathogen. While MyD88 expression in T cells during LCMV 
infection appears to be dispensable for initial activation, proliferation, and differentiation 
into fate committed subsets of effectors, it is required for the survival and accumulation 
of effector T cells during the phase of antigen driven proliferation. These findings suggest 
a model (Figure 5.1) in which MyD88 plays an important, indirect role in promoting 
initial T cell activation through APCs in the lymph nodes but also acts directly in effector 
T cells at the site of infection, to provide signals that support the survival and clonal 
expansion. Thus MyD88 may serve as link that allows T cells to directly respond to 
inflammatory stimuli that deliver pro-survival signals during viral infection. At this point, 
the nature of the inflammatory stimuli that link MyD88 to T cell survival remain unclear 
and raises the possibility that the importance of MyD88 may be related to functions 
outside of it traditional role in TLR signaling during LCMV infection. Overall, by 
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broadening the importance of MyD88 in T cells, our findings support a shift in the dogma 
that restricts the role MyD88 to cells of the innate immune system and may have 
significant implications for understanding the signals that control T cell survival during 
inflammatory immune responses. 
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Figure 5.1. Model for the direct and indirect contributions of MyD88 to T cell responses 
during infection. 
 
 
 
113 
 
Bibliography 
 
Adachi, O. et al., 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-
mediated function. Immunity, 9(1), 143-150. 
 
Aichele, P. et al., 2006. CD8 T cells specific for lymphocytic choriomeningitis virus require type I 
IFN receptor for clonal expansion. Journal of Immunology (Baltimore, Md.: 1950), 
176(8), 4525-4529. 
 
Akashi, S. et al., 2000. Cutting edge: cell surface expression and lipopolysaccharide signaling via 
the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. Journal of 
Immunology (Baltimore, Md.: 1950), 164(7), 3471-3475. 
 
Alexopoulou, L. et al., 2001. Recognition of double-stranded RNA and activation of NF-kappaB 
by Toll-like receptor 3. Nature, 413(6857), 732-738. 
 
Aliprantis, A.O. et al., 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-
like receptor-2. Science (New York, N.Y.), 285(5428), 736-739. 
 
Allam, A. et al., 2009. The CD8+ memory T-cell state of readiness is actively maintained and 
reversible. Blood, 114(10), 2121-2130. 
 
Altemeier, W.A. et al., 2007. Fas (CD95) induces macrophage proinflammatory chemokine 
production via a MyD88-dependent, caspase-independent pathway. J Leukoc Biol, 82(3), 
721-728. 
 
Balkhi, M.Y., Fitzgerald, K.A. & Pitha, P.M., 2008a. Functional regulation of MyD88-activated 
interferon regulatory factor 5 by K63-linked polyubiquitination. Molecular and Cellular 
Biology, 28(24), 7296-7308. 
 
114 
 
Balkhi, M.Y., Fitzgerald, K.A. & Pitha, P.M., 2008b. Functional Regulation of MyD88-Activated 
Interferon Regulatory Factor 5 by K63-Linked Polyubiquitination . Mol. Cell. Biol., 28(24), 
7296-7308. 
 
Bartholdy, C. et al., 2009. T-cell intrinsic expression of MyD88 is required for sustained 
expansion of the virus-specific CD8+ T-cell population in LCMV-infected mice. The 
Journal of General Virology, 90(Pt 2), 423-431. 
 
Barton, G.M., Kagan, J.C. & Medzhitov, R., 2006. Intracellular localization of Toll-like receptor 9 
prevents recognition of self DNA but facilitates access to viral DNA. Nature Immunology, 
7(1), 49-56. 
 
Bendigs, S. et al., 1999. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence 
of antigen-presenting cells. European Journal of Immunology, 29(4), 1209-1218. 
 
Bianchi, M.E., 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of 
Leukocyte Biology, 81(1), 1-5. 
 
Blander, J.M. & Medzhitov, R., 2006. Toll-dependent selection of microbial antigens for 
presentation by dendritic cells. Nature, 440(7085), 808-812. 
 
Boone, D.L. et al., 2004. The ubiquitin-modifying enzyme A20 is required for termination of Toll-
like receptor responses. Nature Immunology, 5(10), 1052-1060. 
 
Caramalho, I. et al., 2003. Regulatory T Cells Selectively Express Toll-like Receptors and Are 
Activated by Lipopolysaccharide. J. Exp. Med., 197(4), 403-411. 
 
Caron, G. et al., 2005. Direct Stimulation of Human T Cells via TLR5 and TLR7/8: Flagellin and R-
848 Up-Regulate Proliferation and IFN-{gamma} Production by Memory CD4+ T Cells. J 
Immunol, 175(3), 1551-1557. 
 
Chiffoleau, E. et al., 2007. TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates 
suppressive activity mediated by CD4+ CD25+ T cell. Int. Immunol., 19(2), 193-201. 
115 
 
 
Christensen, S.R. et al., 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and 
have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity, 
25(3), 417-428. 
 
Chuang, T. & Ulevitch, R.J., 2004. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like 
receptors. Nature Immunology, 5(5), 495-502. 
 
Cong, Y. et al., 1998. CD4+ T Cells Reactive to Enteric Bacterial Antigens in Spontaneously Colitic 
C3H/HeJBir Mice: Increased T Helper Cell Type 1 Response and Ability to Transfer 
Disease. J. Exp. Med., 187(6), 855-864. 
 
Cottalorda, A. et al., 2009. TLR2 engagement on memory CD8(+) T cells improves their cytokine-
mediated proliferation and IFN-gamma secretion in the absence of Ag. European Journal 
of Immunology. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19634192 
[Accessed September 23, 2009]. 
 
Cottalorda, A. et al., 2006. TLR2 engagement on CD8 T cells lowers the thresholdfor optimal 
antigen-induced T cell activation. European Journal of Immunology, 36(7), 1684-1693. 
 
Crellin, N.K. et al., 2005. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the 
suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. Journal 
of Immunology (Baltimore, Md.: 1950), 175(12), 8051-8059. 
 
Curtsinger, J.M. et al., 2005. Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to 
Stimulate Clonal Expansion and Differentiation. J Immunol, 174(8), 4465-4469. 
 
Debierre-Grockiego, F. et al., 2007. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols 
derived from Toxoplasma gondii. Journal of Immunology (Baltimore, Md.: 1950), 179(2), 
1129-1137. 
 
Delale, T. et al., 2005. MyD88-dependent and -independent murine cytomegalovirus sensing for 
IFN-alpha release and initiation of immune responses in vivo. Journal of Immunology 
(Baltimore, Md.: 1950), 175(10), 6723-6732. 
116 
 
 
Dennis, G. et al., 2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery. 
Genome Biology, 4(5), P3. 
 
Denton, A.E. et al., 2007. IL-18, but not IL-12, is required for optimal cytokine production by 
influenza virus-specific CD8+ T cells. European Journal of Immunology, 37(2), 368-375. 
 
Ehlers, M. et al., 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a 
and 2b autoantibodies in SLE. The Journal of Experimental Medicine, 203(3), 553-561. 
 
Fearon, D.T. & Locksley, R.M., 1996. The instructive role of innate immunity in the acquired 
immune response. Science (New York, N.Y.), 272(5258), 50-53. 
 
Fukata, M. et al., 2008. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell 
effector function in a murine model of inflammatory bowel disease. Journal of 
Immunology (Baltimore, Md.: 1950), 180(3), 1886-1894. 
 
Gao, B. & Tsan, M., 2003a. Endotoxin contamination in recombinant human heat shock protein 
70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha 
release by murine macrophages. The Journal of Biological Chemistry, 278(1), 174-179. 
 
Gao, B. & Tsan, M., 2003b. Recombinant human heat shock protein 60 does not induce the 
release of tumor necrosis factor alpha from murine macrophages. The Journal of 
Biological Chemistry, 278(25), 22523-22529. 
 
Gelman, A.E. et al., 2006. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T 
cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity, 25(5), 
783-93. 
 
Gelman, A.E. et al., 2004. Toll-like receptor ligands directly promote activated CD4+ T cell 
survival. Journal of Immunology (Baltimore, Md.: 1950), 172(10), 6065-73. 
 
117 
 
Gewirtz, A.T. et al., 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 
to induce epithelial proinflammatory gene expression. Journal of Immunology 
(Baltimore, Md.: 1950), 167(4), 1882-1885. 
 
Giordani, L. et al., 2009. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig 
production. Journal of Leukocyte Biology, 86(2), 261-271. 
 
Gramaglia, I. et al., 2000. The OX40 costimulatory receptor determines the development of CD4 
memory by regulating primary clonal expansion. Journal of Immunology (Baltimore, 
Md.: 1950), 165(6), 3043-3050. 
 
Hayashi, F. et al., 2001. The innate immune response to bacterial flagellin is mediated by Toll-
like receptor 5. Nature, 410(6832), 1099-1103. 
 
Heil, F. et al., 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 
and 8. Science (New York, N.Y.), 303(5663), 1526-1529. 
 
Hemmi, H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature, 408(6813), 740-
745. 
 
Hertz, C.J. et al., 2001. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like 
receptor 2. Journal of Immunology (Baltimore, Md.: 1950), 166(4), 2444-2450. 
 
Hitziger, N. et al., 2005. Dissemination of Toxoplasma gondii to immunoprivileged organs and 
role of Toll/interleukin-1 receptor signalling for host resistance assessed by in vivo 
bioluminescence imaging. Cellular Microbiology, 7(6), 837-848. 
 
Honda, K. et al., 2004. Role of a transductional-transcriptional processor complex involving 
MyD88 and IRF-7 in Toll-like receptor signaling. Proceedings of the National Academy of 
Sciences of the United States of America, 101(43), 15416-15421. 
 
Honda, K. et al., 2005. IRF-7 is the master regulator of type-I interferon-dependent immune 
responses. Nature, 434(7034), 772-777. 
118 
 
 
Hornung, V. et al., 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular 
subsets of human peripheral blood mononuclear cells and sensitivity to CpG 
oligodeoxynucleotides. Journal of Immunology (Baltimore, Md.: 1950), 168(9), 4531-
4537. 
 
Hou, B., Reizis, B. & DeFranco, A.L., 2008. Toll-like receptors activate innate and adaptive 
immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity, 29(2), 
272-282. 
 
Hou, S. et al., 1994. Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature, 
369(6482), 652-654. 
 
Hsu, H., Xiong, J. & Goeddel, D.V., 1995. The TNF receptor 1-associated protein TRADD signals 
cell death and NF-κB activation. Cell, 81(4), 495-504. 
 
Huang, D.W., Sherman, B.T. & Lempicki, R.A., 2009. Systematic and integrative analysis of large 
gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44-57. 
 
Iwaki, D. et al., 2002. The extracellular toll-like receptor 2 domain directly binds peptidoglycan 
derived from Staphylococcus aureus. The Journal of Biological Chemistry, 277(27), 
24315-24320. 
 
Janeway, C.A. & Medzhitov, R., 2002. Innate immune recognition. Annual Review of 
Immunology, 20, 197-216. 
 
Jeong, J. et al., 2004. Hedgehog signaling in the neural crest cells regulates the patterning and 
growth of facial primordia. Genes & Development, 18(8), 937-951. 
 
Jiang, Q. et al., 2000. Lipopolysaccharide induces physical proximity between CD14 and toll-like 
receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. Journal of Immunology 
(Baltimore, Md.: 1950), 165(7), 3541-3544. 
 
119 
 
Jin, M.S. et al., 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-
acylated lipopeptide. Cell, 130(6), 1071-1082. 
 
Jin, M.S. & Lee, J., 2008. Structures of the toll-like receptor family and its ligand complexes. 
Immunity, 29(2), 182-191. 
 
Jung, A. et al., 2008. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells 
and induces a cytotoxic T-cell response via MyD88. Journal of Virology, 82(1), 196-206. 
 
Jurk, M. et al., 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral 
compound R-848. Nature Immunology, 3(6), 499. 
 
Kawai, T. et al., 2004. Interferon-alpha induction through Toll-like receptors involves a direct 
interaction of IRF7 with MyD88 and TRAF6. Nature Immunology, 5(10), 1061-1068. 
 
Kim, H.M. et al., 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin 
antagonist Eritoran. Cell, 130(5), 906-917. 
 
Kolumam, G.A. et al., 2005. Type I interferons act directly on CD8 T cells to allow clonal 
expansion and memory formation in response to viral infection. J. Exp. Med., 202(5), 
637-650. 
 
Komai-Koma, M., Gilchrist, D.S. & Xu, D., 2009. Direct recognition of LPS by human but not 
murine CD8+ T cells via TLR4 complex. European Journal of Immunology, 39(6), 1564-
1572. 
 
Komai-Koma, M. et al., 2004. TLR2 is expressed on activated T cells as a costimulatory receptor. 
Proceedings of the National Academy of Sciences of the United States of America, 
101(9), 3029-3034. 
 
Krug, A. et al., 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial 
stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce 
high amounts of IL-12. European Journal of Immunology, 31(10), 3026-3037. 
120 
 
 
Lancioni, C.L., Thomas, J.J. & Rojas, R.E., 2009. Activation requirements and responses to TLR 
ligands in human CD4+ T cells: comparison of two T cell isolation techniques. Journal of 
Immunological Methods, 344(1), 15-25. 
 
Lang, K.S. et al., 2007. MyD88 protects from lethal encephalitis during infection with vesicular 
stomatitis virus. European Journal of Immunology, 37(9), 2434-2440. 
 
LaRosa, D.F. et al., 2007. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-
dependent costimulation of effector CD4+ T cells. Immunology Letters, 108(2), 183-8. 
 
LaRosa, D.F. et al., 2008. T cell expression of MyD88 is required for resistance to Toxoplasma 
gondii. Proceedings of the National Academy of Sciences of the United States of America, 
105(10), 3855-60. 
 
Latz, E. et al., 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. 
Nature Immunology, 5(2), 190-198. 
 
Lau, C.M. et al., 2005. RNA-associated autoantigens activate B cells by combined B cell antigen 
receptor/Toll-like receptor 7 engagement. The Journal of Experimental Medicine, 202(9), 
1171-1177. 
 
Leadbetter, E.A. et al., 2002. Chromatin-IgG complexes activate B cells by dual engagement of 
IgM and Toll-like receptors. Nature, 416(6881), 603-607. 
 
Lee, P.P. et al., 2001. A critical role for Dnmt1 and DNA methylation in T cell development, 
function, and survival. Immunity, 15(5), 763-774. 
 
Li, C., Zienkiewicz, J. & Hawiger, J., 2005. Interactive sites in the MyD88 Toll/interleukin (IL) 1 
receptor domain responsible for coupling to the IL1beta signaling pathway. The Journal 
of Biological Chemistry, 280(28), 26152-26159. 
 
121 
 
Li, W. et al., 2007. Protection of CD8+ T cells from activation-induced cell death by IL-18. J 
Leukoc Biol, 82(1), 142-151. 
 
Li, X. et al., 2003. Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of 
NF-kappa B in endothelial cells. Infection and Immunity, 71(8), 4414-4420. 
 
Liu, H. et al., 2006. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ 
regulatory T cells. Proceedings of the National Academy of Sciences of the United States 
of America, 103(18), 7048-7053. 
 
Liu, L. et al., 2008. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. 
Science (New York, N.Y.), 320(5874), 379-381. 
 
Loiarro, M. et al., 2009. Identification of critical residues of the MYD88 death domain involved in 
the recruitment of downstream kinases. The Journal of Biological Chemistry. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/19679662 [Accessed September 15, 2009]. 
 
Lucas, P.J. et al., 1995. Naive CD28-deficient T cells can initiate but not sustain an in vitro 
antigen-specific immune response. Journal of Immunology (Baltimore, Md.: 1950), 
154(11), 5757-5768. 
 
Lye, E. et al., 2008. IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive 
immune responses. European Journal of Immunology, 38(3), 870-876. 
 
Mackay, C.R., Marston, W.L. & Dudler, L., 1990. Naive and memory T cells show distinct 
pathways of lymphocyte recirculation. The Journal of Experimental Medicine, 171(3), 
801-817. 
 
Mansson, A., Adner, M. & Cardell, L.O., 2006. Toll-like receptors in cellular subsets of human 
tonsil T cells: altered expression during recurrent tonsillitis. Respiratory Research, 7, 36. 
 
Marta, M. et al., 2008. Unexpected regulatory roles of TLR4 and TLR9 in experimental 
autoimmune encephalomyelitis. European Journal of Immunology, 38(2), 565-575. 
122 
 
 
Martin, M.U. & Wesche, H., 2002. Summary and comparison of the signaling mechanisms of the 
Toll/interleukin-1 receptor family. Biochimica Et Biophysica Acta, 1592(3), 265-280. 
 
Masopust, D., Murali-Krishna, K. & Ahmed, R., 2007. Quantitating the magnitude of the 
lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than 
we thought. Journal of Virology, 81(4), 2002-2011. 
 
Medzhitov, R. et al., 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family 
signaling pathways. Molecular Cell, 2(2), 253-258. 
 
Mercier, B.C. et al., 2009. TLR2 engagement on CD8 T cells enables generation of functional 
memory cells in response to a suboptimal TCR signal. Journal of Immunology (Baltimore, 
Md.: 1950), 182(4), 1860-1867. 
 
Micheau, O. & Tschopp, J., 2003. Induction of TNF receptor I-mediated apoptosis via two 
sequential signaling complexes. Cell, 114(2), 181-190. 
 
Michelsen, K.S. et al., 2001. The role of toll-like receptors (TLRs) in bacteria-induced maturation 
of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC 
maturation and require TLR2. The Journal of Biological Chemistry, 276(28), 25680-
25686. 
 
Morrissey, P. et al., 1993. CD4+ T cells that express high levels of CD45RB induce wasting disease 
when transferred into congenic severe combined immunodeficient mice. Disease 
development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med., 178(1), 
237-244. 
 
van der Most, R.G. et al., 2003. Changing immunodominance patterns in antiviral CD8 T-cell 
responses after loss of epitope presentation or chronic antigenic stimulation. Virology, 
315(1), 93-102. 
 
123 
 
Muzio, M. et al., 2000. Differential expression and regulation of toll-like receptors (TLR) in 
human leukocytes: selective expression of TLR3 in dendritic cells. Journal of Immunology 
(Baltimore, Md.: 1950), 164(11), 5998-6004. 
 
Netea, M.G. et al., 2004. Toll-Like Receptor 2 Suppresses Immunity against Candida albicans 
through Induction of IL-10 and Regulatory T Cells. J Immunol, 172(6), 3712-3718. 
 
Nguyen, L.T. et al., 2000. TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion 
after virus infection but contribute to peptide-induced deletion under limited 
conditions. European Journal of Immunology, 30(2), 683-688. 
 
Oettinger, M.A. et al., 1990. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J 
recombination. Science (New York, N.Y.), 248(4962), 1517-1523. 
 
Ohashi, K. et al., 2000. Cutting edge: heat shock protein 60 is a putative endogenous ligand of 
the toll-like receptor-4 complex. Journal of Immunology (Baltimore, Md.: 1950), 164(2), 
558-561. 
 
Ohnishi, H. et al., 2009. Structural basis for the multiple interactions of the MyD88 TIR domain in 
TLR4 signaling. Proceedings of the National Academy of Sciences of the United States of 
America, 106(25), 10260-10265. 
 
Okamura, Y. et al., 2001. The extra domain A of fibronectin activates Toll-like receptor 4. The 
Journal of Biological Chemistry, 276(13), 10229-10233. 
 
Ozinsky, A. et al., 2000. The repertoire for pattern recognition of pathogens by the innate 
immune system is defined by cooperation between toll-like receptors. Proceedings of 
the National Academy of Sciences of the United States of America, 97(25), 13766-13771. 
 
Park, E.J. et al., 2008. System for tamoxifen-inducible expression of cre-recombinase from the 
Foxa2 locus in mice. Developmental Dynamics: An Official Publication of the American 
Association of Anatomists, 237(2), 447-453. 
 
124 
 
Pasare, C. & Medzhitov, R., 2005. Control of B-cell responses by Toll-like receptors. Nature, 
438(7066), 364-368. 
 
Pasare, C. & Medzhitov, R., 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-
mediated suppression by dendritic cells. Science (New York, N.Y.), 299(5609), 1033-
1036. 
 
Pasare, C. & Medzhitov, R., 2004. Toll-dependent control mechanisms of CD4 T cell activation. 
Immunity, 21(5), 733-741. 
 
Patole, P.S. et al., 2005. Viral double-stranded RNA aggravates lupus nephritis through Toll-like 
receptor 3 on glomerular mesangial cells and antigen-presenting cells. Journal of the 
American Society of Nephrology: JASN, 16(5), 1326-1338. 
 
Pearce, E.L. et al., 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. 
Nature, 460(7251), 103-107. 
 
Peng, G. et al., 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. 
Science (New York, N.Y.), 309(5739), 1380-1384. 
 
Piccirillo, C.A. & Shevach, E.M., 2004. Naturally-occurring CD4+CD25+ immunoregulatory T cells: 
central players in the arena of peripheral tolerance. Seminars in Immunology, 16(2), 81-
88. 
 
Pircher, H. et al., 1989. Tolerance induction in double specific T-cell receptor transgenic mice 
varies with antigen. Nature, 342(6249), 559-561. 
 
Powrie, F. et al., 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from 
chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol., 5(11), 1461-1471. 
 
Quigley, M. et al., 2009. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal 
expansion and memory formation following vaccinia viral infection. Blood, 113(10), 
2256-2264. 
125 
 
 
Rahman, A.H., Taylor, D.K. & Turka, L.A., 2009. The contribution of direct TLR signaling to T cell 
responses. Immunologic Research, 45(1), 25-36. 
 
Refaeli, Y. et al., 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. 
Immunity, 8(5), 615-623. 
 
Rhee, S.H. et al., 2003. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by 
distinct mechanisms in macrophages. The Journal of Biological Chemistry, 278(25), 
22506-22512. 
 
Rhee, S.H. et al., 2006. Role of MyD88 in phosphatidylinositol 3-kinase activation by 
flagellin/toll-like receptor 5 engagement in colonic epithelial cells. The Journal of 
Biological Chemistry, 281(27), 18560-18568. 
 
Rudd, B.D. et al., 2008. Cutting edge: TLR ligands increase TCR triggering by slowing peptide-
MHC class I decay rates. Journal of Immunology (Baltimore, Md.: 1950), 181(8), 5199-
5203. 
 
Ruprecht, C.R. & Lanzavecchia, A., 2006. Toll-like receptor stimulation as a third signal required 
for activation of human naive B cells. European Journal of Immunology, 36(4), 810-816. 
 
Ruzankina, Y. et al., 2007. Deletion of the developmentally essential gene ATR in adult mice 
leads to age-related phenotypes and stem cell loss. Cell Stem Cell, 1(1), 113-126. 
 
Sartor, R.B., 2001. Induction of mucosal immune responses by bacteria and bacterial 
components. Current Opinion in Gastroenterology, 17(6), 555-561. 
 
Scanga, C.A. et al., 2002. Cutting Edge: MyD88 Is Required for Resistance to Toxoplasma gondii 
Infection and Regulates Parasite-Induced IL-12 Production by Dendritic Cells. J Immunol, 
168(12), 5997-6001. 
 
126 
 
Scanga, C.A. et al., 2004. MyD88-Deficient Mice Display a Profound Loss in Resistance to 
Mycobacterium tuberculosis Associated with Partially Impaired Th1 Cytokine and Nitric 
Oxide Synthase 2 Expression. Infect. Immun., 72(4), 2400-2404. 
 
Schmitz, J. et al., 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-
related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23(5), 
479-490. 
 
Sharpe, A.H. & Freeman, G.J., 2002. The B7-CD28 superfamily. Nature Reviews. Immunology, 
2(2), 116-126. 
 
Shaulov, A. & Murali-Krishna, K., 2008. CD8 T Cell Expansion and Memory Differentiation Are 
Facilitated by Simultaneous and Sustained Exposure to Antigenic and Inflammatory 
Milieu. J Immunol, 180(2), 1131-1138. 
 
Singh, A. & Suresh, M., 2007. A role for TNF in limiting the duration of CTL effector phase and 
magnitude of CD8 T cell memory. Journal of Leukocyte Biology, 82(5), 1201-1211. 
 
Slifka, M.K., Whitmire, J.K. & Ahmed, R., 1997. Bone marrow contains virus-specific cytotoxic T 
lymphocytes. Blood, 90(5), 2103-2108. 
 
Sobek, V. et al., 2004. Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse 
system as a basis for chronic inflammatory joint disease. Arthritis Research & Therapy, 
6(5), R433-446. 
 
Sørensen, L.N. et al., 2008. TLR2 and TLR9 synergistically control herpes simplex virus infection 
in the brain. Journal of Immunology (Baltimore, Md.: 1950), 181(12), 8604-8612. 
 
Sun, D. & Ding, A., 2006. MyD88-mediated stabilization of interferon-gamma-induced cytokine 
and chemokine mRNA. Nature Immunology, 7(4), 375-381. 
 
Surh, C.D. & Sprent, J., 2008. Homeostasis of naive and memory T cells. Immunity, 29(6), 848-
862. 
127 
 
 
Sutmuller, R.P.M. et al., 2006. Toll-like receptor 2 controls expansion and function of regulatory 
T cells. The Journal of Clinical Investigation, 116(2), 485-494. 
 
Takaoka, A. et al., 2005. Integral role of IRF-5 in the gene induction programme activated by 
Toll-like receptors. Nature, 434(7030), 243-249. 
 
Takeda, K., Kaisho, T. & Akira, S., 2003. Toll-like receptors. Annual Review of Immunology, 21, 
335-376. 
 
Tanabe, Y. et al., 2005. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta 
responses in T lymphocytes. Journal of Immunology (Baltimore, Md.: 1950), 174(2), 609-
613. 
 
Tebo, A.E. et al., 2005. Rapid recruitment of virus-specific CD8 T cells restructures 
immunodominance during protective secondary responses. Journal of Virology, 79(20), 
12703-12713. 
 
Tengvall, S. & Harandi, A.M., 2008. Importance of myeloid differentiation factor 88 in innate and 
acquired immune protection against genital herpes infection in mice. Journal of 
Reproductive Immunology, 78(1), 49-57. 
 
Termeer, C. et al., 2002. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like 
receptor 4. The Journal of Experimental Medicine, 195(1), 99-111. 
 
Thompson, L.J. et al., 2006. Innate inflammatory signals induced by various pathogens 
differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and 
memory formation. Journal of Immunology (Baltimore, Md.: 1950), 177(3), 1746-54. 
 
Tomita, T. et al., 2008. MyD88-dependent pathway in T cells directly modulates the expansion of 
colitogenic CD4+ T cells in chronic colitis. Journal of Immunology (Baltimore, Md.: 1950), 
180(8), 5291-5299. 
 
128 
 
Toshchakov, V. et al., 2002. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-
dependent gene expression in macrophages. Nature Immunology, 3(4), 392-398. 
 
Turnbull, E.L. et al., 2005. Intestinal dendritic cell subsets: differential effects of systemic TLR4 
stimulation on migratory fate and activation in vivo. Journal of Immunology (Baltimore, 
Md.: 1950), 174(3), 1374-1384. 
 
Vabulas, R.M. et al., 2001. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to 
activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. The 
Journal of Biological Chemistry, 276(33), 31332-31339. 
 
Van Parijs, L., Ibraghimov, A. & Abbas, A.K., 1996. The roles of costimulation and Fas in T cell 
apoptosis and peripheral tolerance. Immunity, 4(3), 321-328. 
 
Wang, X.Z., Brehm, M.A. & Welsh, R.M., 2004. Preapoptotic phenotype of viral epitope-specific 
CD8 T cells precludes memory development and is an intrinsic property of the epitope. 
Journal of Immunology (Baltimore, Md.: 1950), 173(8), 5138-5147. 
 
Weant, A.E. et al., 2008. Apoptosis regulators Bim and Fas function concurrently to control 
autoimmunity and CD8+ T cell contraction. Immunity, 28(2), 218-230. 
 
Wesch, D. et al., 2006. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma 
delta T lymphocytes. Journal of Immunology (Baltimore, Md.: 1950), 176(3), 1348-1354. 
 
Wesche, H. et al., 1997. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. 
Immunity, 7(6), 837-847. 
 
Wherry, E.J. et al., 2003. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue 
Distribution and Results in Distinct Stages of Functional Impairment. J. Virol., 77(8), 
4911-4927. 
 
129 
 
Whitmire, J.K., Tan, J.T. & Whitton, J.L., 2005. Interferon-gamma acts directly on CD8+ T cells to 
increase their abundance during virus infection. The Journal of Experimental Medicine, 
201(7), 1053-1059. 
 
Wojciechowski, S. et al., 2006. Bim mediates apoptosis of CD127(lo) effector T cells and limits T 
cell memory. European Journal of Immunology, 36(7), 1694-1706. 
 
Wojciechowski, S. et al., 2007. Bim/Bcl-2 balance is critical for maintaining naive and memory T 
cell homeostasis. The Journal of Experimental Medicine, 204(7), 1665-1675. 
 
Wong, R.M. et al., 2009. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated 
PD-1 expression. Immunology Letters. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19751765 [Accessed September 26, 2009]. 
 
Yamamoto, M. et al., 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor 
signaling pathway. Science (New York, N.Y.), 301(5633), 640-643. 
 
Yamamoto, M. et al., 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter 
that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. 
Journal of Immunology (Baltimore, Md.: 1950), 169(12), 6668-6672. 
 
Yarovinsky, F. et al., 2005. TLR11 activation of dendritic cells by a protozoan profilin-like protein. 
Science (New York, N.Y.), 308(5728), 1626-1629. 
 
Yi, A.K. et al., 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from 
spontaneous apoptosis and promote cell cycle entry. Journal of Immunology (Baltimore, 
Md.: 1950), 160(12), 5898-5906. 
 
Zanin-Zhorov, A. et al., 2006. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell 
function via innate TLR2 signaling. The Journal of Clinical Investigation, 116(7), 2022-
2032. 
 
130 
 
Zanin-Zhorov, A. et al., 2007. Cutting edge: T cells respond to lipopolysaccharide innately via 
TLR4 signaling. Journal of Immunology (Baltimore, Md.: 1950), 179(1), 41-44. 
 
Zarember, K.A. & Godowski, P.J., 2002. Tissue expression of human Toll-like receptors and 
differential regulation of Toll-like receptor mRNAs in leukocytes in response to 
microbes, their products, and cytokines. Journal of Immunology (Baltimore, Md.: 1950), 
168(2), 554-561. 
 
Zhande, R. et al., 2007. FADD negatively regulates lipopolysaccharide signaling by impairing 
interleukin-1 receptor-associated kinase 1-MyD88 interaction. Molecular and Cellular 
Biology, 27(21), 7394-7404. 
 
Zhang, D. et al., 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. 
Science (New York, N.Y.), 303(5663), 1522-1526. 
 
Zhao, Y. et al., 2009. The Adaptor Molecule MyD88 Directly Promotes CD8 T Cell Responses to 
Vaccinia Virus. J Immunol, 182(10), 6278-6286. 
 
Zhou, S. et al., 2008. Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells 
results in TLR2-MyD88/Mal-dependent inflammatory responses. Journal of 
Neuroimmunology, 194(1-2), 70-82. 
 
Zhou, S. et al., 2005. MyD88 is critical for the development of innate and adaptive immunity 
during acute lymphocytic choriomeningitis virus infection. European Journal of 
Immunology, 35(3), 822-830. 
 
Zhou, S. et al., 2002. Critical role for perforin-, Fas/FasL-, and TNFR1-mediated cytotoxic 
pathways in down-regulation of antigen-specific T cells during persistent viral infection. 
Journal of Virology, 76(2), 829-840. 
 
Zhu, J. et al., 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-
independent production of IFN-beta. Blood, 109(2), 619-625. 
